



National Health (Pharmaceutical benefits— early supply) Instrument 2015

PB 120 of 2015

made under subsection 84AAA(2) of the

National Health Act 1953

Compilation No. 105

Compilation date: 1 July 2025

Includes amendments: F2025L00776

Prepared by the Office of Parliamentary Counsel, Canberra

About this compilation

This compilation

This is a compilation of the *National Health (Pharmaceutical benefits—early supply) Instrument 2015* that shows the text of the law as amended and in force on 1 July 2025 (the *compilation date*).

The notes at the end of this compilation (the *endnotes*) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1	Name of Instrument.....	1
4	Definitions.....	1
5	Specification of pharmaceutical items	2
6	Circumstances relating to specification of pharmaceutical items in Schedule 1	2
7	Circumstances relating to specification of pharmaceutical items in Schedule 2	3
8	Specification of period relating to a pharmaceutical benefit.....	3
Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply		4
Schedule 2—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units		73
Endnotes		125
Endnote 1—About the endnotes		125
Endnote 2—Abbreviation key		126
Endnote 3—Legislation history		127
Endnote 4—Amendment history		135

1 Name of Instrument

- (1) This Instrument is the *National Health (Pharmaceutical benefits—early supply) Instrument 2015*.
- (2) This Instrument may also be cited as PB 120 of 2015.

4 Definitions

- (1) In this Instrument:

Act means the *National Health Act 1953*.

g means grams.

I.U. means international unit.

mg means milligram.

mL means millilitre.

pharmaceutical benefit has the meaning given by section 84 of the Act.

pharmaceutical item has the meaning given by section 84AB of the Act.

purposes code has the same meaning as in the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012*.

relevant previous supply means the most recent previous supply to a person of:

- (a) the same pharmaceutical benefit; or
- (b) another pharmaceutical benefit that has the same pharmaceutical item as the pharmaceutical benefit; or
- (c) another pharmaceutical benefit that is Schedule equivalent to the pharmaceutical benefit.

relevant purpose, for a pharmaceutical benefit, means a purpose, mentioned in Schedule 4 of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* for a purposes code specified in Schedule 1 of that instrument for the pharmaceutical benefit, that includes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

Schedule equivalent has the same meaning as in Part VII of the Act.

- (2) A reference in this instrument to supply on the basis of a prescription includes reference to supply on the basis of a repeat authorisation or deferred supply authorisation.

5 Specification of pharmaceutical items

- (1) A pharmaceutical item in a pharmaceutical benefit is specified for paragraph 84AAA(1)(a) of the Act if subsection (2) or (3) applies in relation to the pharmaceutical item.
- (2) This subsection applies if:
 - (a) the listed drug and the form of that listed drug in the pharmaceutical item are mentioned in the table in Schedule 1; and
 - (b) all the circumstances identified in section 6 exist in relation to a benefit that has the listed drug and form in the table in Schedule 1.
- (3) This subsection applies if:
 - (a) the listed drug and the form of that listed drug in the pharmaceutical item are mentioned in the table in Schedule 2; and
 - (b) all the circumstances identified in section 7 exist in relation to a pharmaceutical benefit that has the listed drug and form in the table in Schedule 2.

Note: All pharmaceutical items have a manner of administration determined under subsection 85(5) of the Act, so the listed drug in that form with that manner of administration is specified.

6 Circumstances relating to specification of pharmaceutical items in Schedule 1

- (1) For paragraph 5(2)(b), the circumstances are as follows:
 - (a) the form mentioned in the table in Schedule 1 of a pharmaceutical benefit that has the listed drug is the same as the form determined under subsection 85(3) of the Act;
 - (b) a maximum quantity or number of units mentioned in the table in Schedule 1 for a benefit that has the listed drug and form is the same as a maximum quantity or number of units determined under paragraph 85A(2)(a) of the Act;
 - (c) a maximum number of repeats mentioned in the table in Schedule 1 for a benefit that has the listed drug and form is the same as a maximum number of repeats determined under paragraph 85A(2)(b) of the Act;
 - (d) where the supply of the pharmaceutical benefit was made on the basis of a prescription – the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was not directed for a relevant purpose for the pharmaceutical benefit; and
 - (e) any other circumstance for paragraph 84AAA(3)(b) of the Act that is mentioned in the table in Schedule 1 for a benefit that has the listed drug and form.

7 Circumstances relating to specification of pharmaceutical items in Schedule 2

- (1) For paragraph 5(3)(b), the circumstances are as follows:
 - (a) the form mentioned in the table in Schedule 2 of a pharmaceutical benefit that has the listed drug is the same as the form determined under subsection 85(3) of the Act;
 - (b) a maximum quantity or number of units mentioned in the table in Schedule 2 for a benefit that has the listed drug and form is the same as a maximum quantity or number of units determined under paragraph 85A(2)(a) of the Act;
 - (c) a maximum number of repeats mentioned in the table in Schedule 2 for a pharmaceutical benefit that has the listed drug and form is the same as a maximum number of repeats determined under paragraph 85A(2)(b) of the Act;
 - (d) the pharmaceutical benefit was supplied on the basis of a prescription;
 - (e) the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was directed for a relevant purpose for the pharmaceutical benefit; and
 - (f) any other circumstance for paragraph 84AAA(3)(b) of the Act that is mentioned in the table in Schedule 2 for a benefit that has the listed drug and form.

8 Specification of period relating to a pharmaceutical benefit

- (1) This section is made for paragraph 84AAA(1)(b) of the Act.
- (2) For a pharmaceutical benefit that has the listed drug and the form of the listed drug mentioned in the table in Schedule 1, and the circumstances identified for section 6 apply, the number mentioned under the heading 'Period' in the table in Schedule 1 for the listed drug and form is the period in days.
- (3) For a pharmaceutical benefit that has the listed drug and the form of the listed drug mentioned in the table in Schedule 2, and the circumstances identified for section 7 apply:
 - (a) where the relevant previous supply to the person was on the basis of a prescription and the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was directed for a relevant purpose for the previously supplied pharmaceutical benefit – the number mentioned under the heading 'Period' for the listed drug and form is the period in days;
 - (b) in any other case – the period is 20 days.

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Abatacept	Injection 125 mg in 1 mL single dose autoinjector	20	4	5	
	Injection 125 mg in 1 mL single dose pre-filled syringe	20	4	5	
Abemaciclib	Tablet 50 mg	20	56	5	
	Tablet 100 mg	20	56	5	
	Tablet 150 mg	20	56	5	
Abiraterone	Tablet containing abiraterone acetate 250 mg	20	120	2	
	Tablet containing abiraterone acetate 500 mg	20	60	2	
Acalabrutinib	Tablet 100 mg	20	56	5	
		20	56	6	
Aciclovir	Tablet 200 mg	20	90	5	
Acidinium	Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses	20	1	5	
Acidinium with formoterol	Powder for oral inhalation in breath actuated device containing acidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses	20	1	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Adalimumab	Injection 20 mg in 0.2 mL pre-filled syringe	20	2	0	
		20	2	3	
		20	2	5	
		20	2	6	
	Injection 20 mg in 0.4 mL pre-filled syringe	20	2	0	
		20	2	3	
		20	2	5	
		20	2	6	
	Injection 40 mg in 0.4 mL pre-filled pen	20	2	0	
		20	2	2	
		20	2	5	
		20	2	6	
		20	4	5	
		20	6	0	
		20	2	2	
Injection 40 mg in 0.4 mL pre-filled syringe	20	2	0		
	20	2	2		
	20	2	5		

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	2	6	
		20	6	0	
	Injection 40 mg in 0.8 mL pre-filled pen	20	2	0	
		20	2	2	
		20	2	5	
		20	2	6	
		20	4	5	
		20	6	0	
	Injection 40 mg in 0.8 mL pre-filled syringe	20	2	0	
		20	2	2	
		20	2	5	
		20	2	6	
		20	6	0	
	Injection 80 mg in 0.8 mL pre-filled pen	20	2	5	
		20	3	0	
	Injection 80 mg in 0.8 mL pre-filled syringe	20	2	5	
		20	3	0	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Alendronic acid	Tablet 70 mg (as alendronate sodium)	20	4	5	
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	20	4	5	
	Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	20	4	5	
Allopurinol	Tablet 100 mg	20	200	2	
	Tablet 300 mg	20	60	2	
Alogliptin	Tablet 6.25 mg (as benzoate)	20	28	5	
	Tablet 12.5 mg (as benzoate)	20	28	5	
	Tablet 25 mg (as benzoate)	20	28	5	
Alogliptin with metformin	Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride	20	56	5	
	Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride	20	56	5	
	Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride	20	56	5	
Amantadine	Capsule containing amantadine hydrochloride 100 mg	20	100	5	
Amifampridine	Tablet 10 mg	20	200	5	
Amlodipine	Tablet 5 mg (as besilate)	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Amlodipine with atorvastatin	Tablet 10 mg (as besilate)	20	30	5	
	Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)	20	30	5	
	Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)	20	30	5	
	Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)	20	30	5	
	Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)	20	30	5	
	Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)	20	30	5	
	Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)	20	30	5	
	Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)	20	30	5	
Amlodipine with valsartan	Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)	20	30	5	
	Tablet 5 mg (as besilate)-80 mg	20	28	5	
	Tablet 5 mg (as besilate)-160 mg	20	28	5	
	Tablet 5 mg (as besilate)-320 mg	20	28	5	
	Tablet 10 mg (as besilate)-160 mg	20	28	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Amlodipine with valsartan and hydrochlorothiazide	Tablet 10 mg (as besilate)-320 mg	20	28	5	
	Tablet 5 mg (as besilate)-160 mg-12.5 mg	20	28	5	
	Tablet 5 mg (as besilate)-160 mg-25 mg	20	28	5	
	Tablet 10 mg (as besilate)-160 mg-12.5 mg	20	28	5	
	Tablet 10 mg (as besilate)-160 mg-25 mg	20	28	5	
	Tablet 10 mg (as besilate)-320 mg-25 mg	20	28	5	
Anastrozole	Tablet 1 mg	20	30	5	
Apalutamide	Tablet 60 mg	20	120	5	
Apixaban	Tablet 2.5 mg	20	60	0	
		20	60	5	
	Tablet 5 mg	20	28	0	
Armodafinil	Tablet 50 mg	20	60	5	
		20	30	5	
		20	30	5	
Asciminib	Tablet 20 mg	20	60	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 40 mg	20	60	5	
		20	300	5	
Aspirin	Tablet 100 mg	20	112	1	
Atazanavir with cobicistat	Tablet containing 300 mg atazanavir and 150 mg cobicistat	20	60	5	
Atenolol	Oral solution 50 mg in 10 mL, 300 mL	20	1	5	
	Tablet 50 mg	20	30	5	
Atomoxetine	Capsule 10 mg (as hydrochloride)	20	56	5	
	Capsule 18 mg (as hydrochloride)	20	56	5	
	Capsule 25 mg (as hydrochloride)	20	56	5	
	Capsule 40 mg (as hydrochloride)	20	56	5	
	Capsule 60 mg (as hydrochloride)	20	56	5	
	Capsule 80 mg (as hydrochloride)	20	28	5	
	Capsule 100 mg (as hydrochloride)	20	28	5	
Atorvastatin	Tablet 10 mg (as calcium)	20	30	5	
	Tablet 20 mg (as calcium)	20	30	5	
	Tablet 40 mg (as calcium)	20	30	5	
	Tablet 80 mg (as calcium)	20	30	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Auranofin	Capsule 3 mg	20	60	5	
	Tablet 3 mg	20	60	5	
Azacitidine	Tablet 200 mg	20	14	2	
	Tablet 300 mg	20	14	2	
		20	21	1	
Azathioprine	Tablet 25 mg	20	100	5	
	Tablet 50 mg	20	100	5	
Baclofen	Tablet 10 mg	20	100	5	
	Tablet 25 mg	20	100	5	
Balsalazide	Capsule containing balsalazide sodium 750 mg	20	280	5	
Baricitinib	Tablet 2 mg	20	28	5	
	Tablet 4 mg	20	28	5	
Beclometasone with formoterol and glycopyrronium	Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses	20	1	5	
	Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses	20	1	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Betaine	Oral powder 180 g	20	1	5	
Betamethasone	Injection containing betamethasone acetate 3 mg with betamethasone sodium phosphate 3.9 mg in 1 mL	20	5	0	
Bicalutamide	Tablet 50 mg	20	28	5	
Bictegravir with emtricitabine with tenofovir alafenamide	Tablet containing bictegravir 50 mg with emtricitabine 200 mg with tenofovir alafenamide 25 mg	20	60	5	
Bimekizumab	Injection 160 mg in 1 mL single use pre-filled pen	20	2	1	
		20	2	2	
		20	2	4	
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	20	28	5	
	Tablet containing bisoprolol fumarate 5 mg	20	28	5	
	Tablet containing bisoprolol fumarate 10 mg	20	28	5	
Brexipiprazole	Tablet 1 mg	20	30	0	
	Tablet 2 mg	20	30	5	
	Tablet 3 mg	20	30	5	
	Tablet 4 mg	20	30	5	
Brivaracetam	Oral solution 10 mg per mL, 300 mL	20	1	5	
	Tablet 25 mg	20	56	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 50 mg	20	56	5	
	Tablet 75 mg	20	56	5	
	Tablet 100 mg	20	56	5	
Budesonide with glycopyrronium and formoterol	Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses	20	1	5	
Buprenorphine	Injection (modified release) 8 mg in 0.16 mL pre-filled syringe	20	4	5	
	Injection (modified release) 16 mg in 0.32 mL pre-filled syringe	20	4	5	
	Injection (modified release) 24 mg in 0.48 mL pre-filled syringe	20	4	5	
	Injection (modified release) 32 mg in 0.64 mL pre-filled syringe	20	4	5	
	Injection (modified release) 64 mg in 0.18 mL pre-filled syringe	20	1	5	
	Injection (modified release) 96 mg in 0.27 mL pre-filled syringe	20	1	5	
	Injection (modified release) 100 mg in 0.5 mL pre-filled syringe	20	1	5	
	Injection (modified release) 128 mg in 0.36 mL pre-filled syringe	20	1	5	
	Injection (modified release) 160 mg in 0.45 mL pre-filled syringe	20	1	5	
	Injection (modified release) 300 mg in 1.5 mL pre-filled syringe	20	1	5	
	Tablet (sublingual) 400 micrograms (as hydrochloride)	20	28	5	
	Tablet (sublingual) 2 mg (as hydrochloride)	20	84	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet (sublingual) 8 mg (as hydrochloride)	20	112	5	
Buprenorphine with naloxone	Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	20	84	5	
	Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	20	112	5	
Bupropion	Tablet containing bupropion hydrochloride 150 mg (sustained release)	20	30	0	
		20	90	0	
Cabergoline	Tablet 1 mg	20	30	5	
	Tablet 2 mg	20	30	5	
Cabozantinib	Tablet 20 mg	20	30	2	
		20	30	5	
	Tablet 40 mg	20	30	2	
		20	30	5	
	Tablet 60 mg	20	30	2	
		20	30	5	
Calcitonin salmon	Injection 100 I.U. in 1 mL	20	15	5	
Calcitriol	Capsule 0.25 microgram	20	100	3	
Calcium	Tablet 600 mg (as carbonate)	20	240	1	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Candesartan	Tablet containing candesartan cilexetil 4 mg	20	30	5	
	Tablet containing candesartan cilexetil 8 mg	20	30	5	
	Tablet containing candesartan cilexetil 16 mg	20	30	5	
	Tablet containing candesartan cilexetil 32 mg	20	30	5	
Candesartan with hydrochlorothiazide	Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg	20	30	5	
Carbamazepine	Tablet 100 mg	20	200	0	
		20	200	2	
	Tablet 200 mg	20	200	0	
		20	200	2	
	Tablet 200 mg (controlled release)	20	200	0	
		20	200	2	
	Tablet 400 mg (controlled release)	20	200	0	
		20	200	2	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Carvedilol	Tablet 6.25 mg	20	60	5	
	Tablet 12.5 mg	20	60	5	
	Tablet 25 mg	20	60	5	
Certolizumab pegol	Injection 200 mg in 1 mL single use pre-filled syringe	20	2	5	
	Solution for injection 200 mg in 1 mL pre-filled pen	20	2	5	
Citalopram	Tablet 20 mg (as hydrobromide)	20	28	5	
	Tablet 40 mg (as hydrobromide)	20	28	5	
Clonazepam	Tablet 2 mg	20	200	2	
	Tablet 500 micrograms	20	200	2	
Clonidine	Tablet containing clonidine hydrochloride 100 micrograms	20	100	5	
	Tablet containing clonidine hydrochloride 150 micrograms	20	100	5	
Clopidogrel	Tablet 75 mg (as besilate)	20	28	5	
	Tablet 75 mg (as hydrogen sulfate)	20	28	5	
Clopidogrel with aspirin	Tablet 75 mg (as hydrogen sulfate)-100 mg	20	30	5	
Dabigatran etexilate	Capsule 75 mg (as mesilate)	20	60	0	
	Capsule 110 mg (as mesilate)	20	60	0	
		20	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Capsule 150 mg (as mesilate)	20	60	5	
Dapagliflozin	Tablet 10 mg (as propanediol monohydrate)	20	28	5	
Dapagliflozin with metformin	Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride	20	56	5	
	Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride	20	28	5	
	Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride	20	28	5	
Dapagliflozin with sitagliptin	Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate)	20	28	5	
Dapsone	Tablet 25 mg	20	100	1	
	Tablet 100 mg	20	100	1	
Darolutamide	Tablet 300 mg	20	112	5	
Darunavir with cobicistat, emtricitabine and tenofovir alafenamide	Tablet containing darunavir 800 mg with cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg	20	60	5	
Dasatinib	Tablet 20 mg	20	60	2	
		20	60	5	
	Tablet 50 mg	20	60	2	
		20	60	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 70 mg	20	60	2	
		20	60	5	
	Tablet 100 mg	20	30	2	
		20	30	5	
Decitabine with cedazuridine	Tablet containing decitabine 35 mg with cedazuridine 100 mg	20	5	2	
		20	5	5	
Degarelix	Powder for injection 80 mg (as acetate), injection set	20	1	5	
	Powder for injection 120 mg (as acetate), 2, injection set	20	1	0	
Denosumab	Injection 60 mg in 1 mL pre-filled syringe	20	1	0	
Desmopressin	Tablet containing desmopressin acetate 200 micrograms	20	30	5	
		20	90	5	
	Wafer 120 micrograms (as acetate)	20	30	5	
	Wafer 240 micrograms (as acetate)	20	30	5	
Desvenlafaxine	Tablet (extended release) 50 mg (as succinate)	20	28	5	
	Tablet (extended release) 100 mg (as succinate)	20	28	5	
	Tablet (modified release) 50 mg	20	28	5	
	Tablet (modified release) 50 mg (as benzoate)	20	28	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet (modified release) 100 mg	20	28	5	
	Tablet (modified release) 100 mg (as benzoate)	20	28	5	
Deucravacitinib	Tablet 6 mg	20	28	5	
Dienogest	Tablet 2 mg	20	28	5	
Digoxin	Tablet 62.5 micrograms	20	200	1	
	Tablet 250 micrograms	20	100	1	
Diltiazem	Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg	20	30	5	
	Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg	20	30	5	
	Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg	20	30	5	
	Tablet containing diltiazem hydrochloride 60 mg	20	90	5	
Dimethyl fumarate	Capsule (modified release) 240 mg	20	56	5	
Diroximel fumarate	Capsule (enteric) 231 mg	20	120	5	
Dolutegravir with lamivudine	Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg	20	60	5	
Dolutegravir with rilpivirine	Tablet containing dolutegravir 50 mg (as sodium) with rilpivirine 25 mg (as hydrochloride)	20	60	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Donepezil	Tablet containing donepezil hydrochloride 5 mg	20	28	5	
	Tablet containing donepezil hydrochloride 10 mg	20	28	5	
Drospirenone	Pack containing 24 tablets 4 mg and 4 inert tablets	20	4	2	
Drospirenone with ethinylestradiol	Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets	20	3	3	
	Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets	20	3	3	
Dulaglutide	Injection 1.5 mg in 0.5 mL single dose pre-filled pen	20	4	5	
Duloxetine	Capsule 60 mg (as hydrochloride)	20	28	5	
Dupilumab	Injection 200 mg in 1.14 mL single dose pre-filled syringe	20	2	5	
	Injection 300 mg in 2 mL single dose pre-filled syringe	20	2	5	
Dutasteride	Capsule 500 micrograms	20	30	5	
Dutasteride with tamsulosin	Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms	20	30	5	
Empagliflozin	Tablet 10 mg	20	30	5	
	Tablet 25 mg	20	30	5	
Empagliflozin with linagliptin	Tablet containing 10 mg empagliflozin with 5 mg linagliptin	20	30	5	
	Tablet containing 25 mg empagliflozin with 5 mg linagliptin	20	30	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Empagliflozin with metformin	Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride	20	60	5	
	Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride	20	60	5	
	Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride	20	60	5	
	Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride	20	60	5	
Enalapril	Tablet containing enalapril maleate 5 mg	20	30	5	
	Tablet containing enalapril maleate 10 mg	20	30	5	
	Tablet containing enalapril maleate 20 mg	20	30	5	
Enalapril with hydrochlorothiazide	Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg	20	30	5	
Entacapone	Tablet 200 mg	20	200	4	
Enzalutamide	Capsule 40 mg	20	112	2	
		20	112	5	
Eplerenone	Tablet 25 mg	20	30	5	
	Tablet 50 mg	20	30	5	
Eprosartan	Tablet 600 mg (as mesilate)	20	28	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Eprosartan with hydrochlorothiazide	Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide	20	28	5	
Erlotinib	Tablet 25 mg (as hydrochloride)	20	30	3	
	Tablet 100 mg (as hydrochloride)	20	30	3	
	Tablet 150 mg (as hydrochloride)	20	30	3	
Escitalopram	Tablet 10 mg (as oxalate)	20	28	5	
	Tablet 20 mg (as oxalate)	20	28	5	
Esomeprazole	Capsule (enteric) 20 mg (as magnesium)	20	30	1	
		20	30	5	
		20	60	5	
	Capsule (enteric) 40 mg (as magnesium)	20	30	1	
		20	30	5	
		20	60	5	
		20	60	5	
	Tablet (enteric coated) 20 mg (as magnesium)	20	30	1	
		20	30	5	
		20	60	5	
Tablet (enteric coated) 40 mg (as magnesium)	20	30	1		

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Esomeprazole and clarithromycin and amoxicillin	Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)	20	30	5	
		20	60	5	
	Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)	20	1	0	
		20	1	0	
Estradiol	Tablet 2 mg	20	56	2	
	Tablet containing estradiol valerate 1 mg	20	56	2	
	Tablet containing estradiol valerate 2 mg	20	56	2	
	Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	20	1	5	
	Transdermal gel 500 micrograms in 0.5 g sachet, 28	20	1	5	
	Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28	20	1	5	
	Transdermal patches 390 micrograms, 8	20	1	5	
	Transdermal patches 390 micrograms, 24 (S19A)	20	1	1	
	Transdermal patches 585 micrograms, 8	20	1	5	
	Transdermal patches 750 micrograms (as hemihydrate), 8	20	1	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Transdermal patches 780 micrograms, 8	20	1	5	
	Transdermal patches 780 micrograms, 24 (S19A)	20	1	1	
	Transdermal patches 1.17 mg, 8	20	1	5	
	Transdermal patches 1.17 mg, 24 (S19A)	20	1	1	
	Transdermal patches 1.5 mg (as hemihydrate), 8	20	1	5	
	Transdermal patches 1.56 mg, 8	20	1	5	
	Transdermal patches 1.56 mg, 24 (Sandoz) (S19A)	20	1	1	
	Transdermal patches 3 mg (as hemihydrate), 8	20	1	5	
Estradiol and estradiol with dydrogesterone	Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg	20	1	5	
	Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg	20	1	5	
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate	20	1	5	
	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate	20	1	5	
Estradiol with norethisterone	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8	20	1	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)	20	1	5	
	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8	20	1	5	
	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)	20	1	5	
Etanercept	Injection 50 mg in 1 mL single use auto-injector, 4	20	1	3	
		20	1	5	
	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	20	2	3	
		20	2	5	
	Injections 50 mg in 1 mL single use pre-filled syringes, 4	20	1	3	
		20	1	5	
Ethosuximide	Capsule 250 mg	20	200	2	
	Capsule 250 mg (s19A)	20	200	2	
Etonogestrel	Subcutaneous implant 68 mg	20	1	0	
Etrasimod	Tablet 2 mg	20	28	3	
		20	28	5	
Evolocumab	Injection 140 mg in 1 mL single use pre-filled pen	20	2	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	3	5	
Ezetimibe	Tablet 10 mg	20	30	5	
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)	20	1	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)	20	1	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)	20	1	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)	20	1	5	
Ezetimibe with atorvastatin	Tablet 10 mg-10 mg	20	30	5	
	Tablet 10 mg-20 mg	20	30	5	
	Tablet 10 mg-40 mg	20	30	5	
	Tablet 10 mg-80 mg	20	30	5	
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	20	30	5	
	Tablet 10 mg-20 mg	20	30	5	
	Tablet 10 mg-40 mg	20	30	5	
	Tablet 10 mg-80 mg	20	30	5	
Famciclovir	Tablet 250 mg	20	56	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 500 mg	20	56	5	
Famotidine	Tablet 20 mg	20	60	5	
	Tablet 40 mg	20	30	5	
Febuxostat	Tablet 80 mg	20	28	5	
Felodipine	Tablet 2.5 mg (extended release)	20	30	5	
	Tablet 5 mg (extended release)	20	30	5	
	Tablet 10 mg (extended release)	20	30	5	
Fenofibrate	Tablet 48 mg	20	60	5	
	Tablet 145 mg	20	30	5	
Fingolimod	Capsule 250 micrograms (as hydrochloride)	20	28	5	
	Capsule 500 micrograms (as hydrochloride)	20	28	5	
Fludarabine	Tablet containing fludarabine phosphate 10 mg	20	20	5	
Fludrocortisone	Tablet containing fludrocortisone acetate 100 micrograms	20	200	1	
Flutamide	Tablet 250 mg	20	100	5	
Fluticasone furoate	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses	20	1	5	
	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses	20	1	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Fluticasone furoate with umeclidinium and vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenate) per dose, 30 doses	20	1	5	
	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenate) per dose, 30 doses	20	1	5	
Fluvastatin	Tablet (prolonged release) 80 mg (as sodium)	20	28	5	
Fluvoxamine	Tablet containing fluvoxamine maleate 50 mg	20	30	5	
	Tablet containing fluvoxamine maleate 100 mg	20	30	5	
Folic acid	Tablet 500 micrograms	20	200	0	
	Tablet 5 mg	20	200	1	
Fosinopril	Tablet containing fosinopril sodium 10 mg	20	30	5	
	Tablet containing fosinopril sodium 20 mg	20	30	5	
Fremanezumab	Solution for injection 225 mg in 1.5 mL single dose pre-filled pen	20	1	2	
		20	1	5	
	Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe	20	1	2	
		20	1	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Furosemide	Tablet 20 mg	20	100	1	
	Tablet 40 mg	20	100	1	
Gabapentin	Capsule 100 mg	20	100	5	
	Capsule 300 mg	20	100	5	
	Capsule 400 mg	20	100	5	
	Tablet 600 mg	20	100	5	
	Tablet 800 mg	20	100	5	
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	20	28	5	
	Capsule (prolonged release) 16 mg (as hydrobromide)	20	28	5	
	Capsule (prolonged release) 24 mg (as hydrobromide)	20	28	5	
Galcanezumab	Injection 120 mg in 1 mL pre-filled pen	20	1	5	
		20	2	1	
Gemfibrozil	Tablet 600 mg	20	60	5	
Gliclazide	Tablet 60 mg (modified release)	20	60	5	
	Tablet 80 mg	20	100	5	
Glimepiride	Tablet 3 mg	20	30	5	
	Tablet 4 mg	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Glyceryl trinitrate	Transdermal patch 18 mg	20	30	5	
	Transdermal patch 25 mg	20	30	5	
	Transdermal patch 36 mg	20	30	5	
	Transdermal patch 50 mg	20	30	5	
	Transdermal patch 54 mg	20	30	5	
Glycopyrronium	Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler)	20	30	5	
Golimumab	Injection 50 mg in 0.5 mL single use pre-filled pen	20	1	5	
	Injection 50 mg in 0.5 mL single use pre-filled syringe	20	1	5	
	Injection 100 mg in 1 mL single use pre-filled pen	20	1	5	
Goserelin	Subcutaneous implant 3.6 mg (as acetate) in pre-filled injection syringe	20	1	5	
	Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre-filled injection syringe	20	1	1	
Goserelin and bicalutamide	Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	20	1	5	
	Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre-filled injection syringe and 28 tablets bicalutamide 50 mg	20	1	0	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre-filled injection syringe and 84 tablets bicalutamide 50 mg	20	1	1	
Griseofulvin	Tablet 125 mg	20	100	2	
Guanfacine	Tablet 1 mg (as hydrochloride)	20	28	5	
	Tablet 2 mg (as hydrochloride)	20	28	5	
	Tablet 3 mg (as hydrochloride)	20	28	5	
	Tablet 4 mg (as hydrochloride)	20	28	5	
Hydrochlorothiazide	Tablet 25 mg	20	100	1	
Hydrochlorothiazide with amiloride	Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg	20	100	1	
Hydroxocobalamin	Injection 1 mg (as acetate) in 1 mL	20	3	0	
	Injection 1 mg (as chloride) in 1 mL	20	3	0	
Hydroxychloroquine	Tablet containing hydroxychloroquine sulfate 200 mg	20	100	1	
Ibandronic acid	Tablet 50 mg (as ibandronate sodium monohydrate)	20	28	2	
Ibrutinib	Capsule 140 mg	20	90	2	
		20	90	4	
		20	90	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	120	5	
	Tablet 280 mg	20	30	2	
		20	30	4	
		20	30	5	
	Tablet 420 mg	20	30	2	
		20	30	4	
		20	30	5	
	Tablet 560 mg	20	30	5	
Icosapent ethyl	Capsule 998 mg	20	120	5	
Idelalisib	Tablet 100 mg	20	60	5	
	Tablet 150 mg	20	60	5	
Imatinib	Capsule 100 mg (as mesilate)	20	60	2	
		20	60	5	
	Capsule 400 mg (as mesilate)	20	30	2	
		20	30	5	
	Tablet 100 mg (as mesilate)	20	60	2	
		20	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 400 mg (as mesilate)	20	30	2	
		20	30	5	
	Tablet 600 mg (as mesilate)	20	30	2	
		20	30	5	
Indacaterol	Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler)	20	30	5	
	Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler)	20	30	5	
Indacaterol with glycopyrronium	Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler)	20	30	5	
Indacaterol with glycopyrronium and mometasone	Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler)	20	30	5	
	Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler)	20	30	5	
Indapamide	Tablet containing indapamide hemihydrate 1.5 mg (sustained release)	20	90	1	
	Tablet containing indapamide hemihydrate 2.5 mg	20	90	1	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Infliximab	Solution for injection 120 mg in 1 mL pre-filled pen	20	1	0	
		20	2	0	
		20	2	2	
		20	2	5	
	Solution for injection 120 mg in 1 mL pre-filled syringe	20	1	0	
		20	2	0	
		20	2	2	
		20	2	5	
Insulin aspart	Injection (human analogue) 100 units per mL, 10 mL vial	20	5	2	
	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
	Injections (human analogue) (fast acting), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
Insulin aspart with insulin aspart protamine suspension	Injections (human analogue), cartridges, 30 units-70 units per mL, 3 mL, 5	20	5	1	
Insulin detemir	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
Insulin glulisine	Injection (human analogue) 100 units per mL, 10 mL	20	5	2	
	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
Insulin isophane	Injection (human) 100 units per mL, 10 mL	20	5	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Insulin lispro	Injections (human), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
	Injection (human analogue) 100 units per mL, 10 mL vial	20	5	2	
	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
	Injections (human analogue), pre-filled pen, 200 units per mL, 3 mL, 5	20	5	1	
Insulin lispro with insulin lispro protamine suspension	Injections (human analogue), cartridges, 25 units-75 units per mL, 3 mL, 5	20	5	1	
	Injections (human analogue), cartridges, 50 units-50 units per mL, 3 mL, 5	20	5	1	
Insulin neutral	Injection (human) 100 units per mL, 10 mL	20	5	2	
	Injections (human), cartridges, 100 units per mL, 3 mL, 5	20	5	1	
Insulin neutral with insulin isophane	Injection (human) 30 units-70 units per mL, 10 mL	20	5	2	
	Injections (human), cartridges, 30 units-70 units per mL, 3 mL, 5	20	5	1	
Irbesartan	Tablet 75 mg	20	30	5	
	Tablet 150 mg	20	30	5	
	Tablet 300 mg	20	30	5	
Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 300 mg-12.5 mg	20	30	5	
	Tablet 300 mg-25 mg	20	30	5	
Isosorbide mononitrate	Tablet 60 mg (sustained release)	20	30	5	
	Tablet 120 mg (sustained release)	20	30	5	
Ivabradine	Tablet 5 mg (as hydrochloride)	20	56	5	
	Tablet 7.5 mg (as hydrochloride)	20	56	5	
Ivosidenib	Tablet 250 mg	20	60	5	
Ixekizumab	Injection 80 mg in 1 mL single dose pre-filled pen	20	2	2	
Ketoprofen	Capsule 200 mg (sustained release)	20	28	0	
		20	28	3	
Labetalol	Tablet containing labetalol hydrochloride 100 mg	20	100	5	
Lacosamide	Tablet 100 mg	20	56	5	
	Tablet 150 mg	20	56	5	
	Tablet 200 mg	20	56	5	
Lamotrigine	Tablet 5 mg	20	56	5	
	Tablet 25 mg	20	56	5	
	Tablet 50 mg	20	56	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Lanadelumab	Tablet 100 mg	20	56	5	
	Tablet 200 mg	20	56	5	
	Injection 300 mg in 2 mL single use pre-filled syringe	20	1	5	
Lansoprazole	Capsule 15 mg	20	30	5	
	Capsule 30 mg	20	28	1	
Leflunomide		20	28	5	
		20	56	5	
	Tablet 15 mg (orally disintegrating)	20	28	5	
	Tablet 30 mg (orally disintegrating)	20	28	1	
		20	28	5	
		20	56	5	
	Tablet 10 mg	20	30	5	
Lercanidipine	Tablet 20 mg	20	30	5	
	Tablet containing lercanidipine hydrochloride 10 mg	20	28	5	
Lercanidipine with enalapril	Tablet containing lercanidipine hydrochloride 20 mg	20	28	5	
	Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg	20	28	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg	20	28	5	
Letrozole	Tablet 2.5 mg	20	30	5	
Leuprorelin	I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe	20	1	1	
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 7.5 mg with diluent in pre-filled dual-chamber syringe	20	1	5	
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 22.5 mg with diluent in pre-filled dual-chamber syringe	20	1	1	
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe	20	1	1	
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 45 mg with diluent in pre-filled dual-chamber syringe	20	1	0	
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set	20	1	5	
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set	20	1	1	
	Suspension for subcutaneous injection (modified release)	20	1	1	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	containing leuprorelin acetate 30 mg, injection set				
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set	20	1	0	
Leuprorelin and bicalutamide	Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg	20	1	5	
	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg	20	1	0	
	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg	20	1	1	
Levetiracetam	Oral solution 100 mg per mL, 300 mL	20	1	5	
	Tablet 250 mg	20	60	5	
	Tablet 500 mg	20	60	5	
	Tablet 1 g	20	60	5	
Levodopa with carbidopa and entacapone	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	20	200	4	
	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	20	200	4	
	Tablet 100 mg-25 mg (as monohydrate)-200 mg	20	200	4	
	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	20	200	4	
	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	20	200	4	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Levonorgestrel	Tablet 200 mg-50 mg (as monohydrate)-200 mg	20	200	4	
	Intrauterine drug delivery system 19.5 mg	20	1	0	
	Intrauterine drug delivery system 52 mg	20	1	0	
Levonorgestrel with ethinylestradiol	Tablets 30 micrograms, 28	20	4	2	
	Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets	20	4	2	
	Pack containing 21 tablets 100 micrograms-20 micrograms and 7 inert tablets	20	4	2	
	Pack containing 21 tablets 125 micrograms-50 micrograms and 7 inert tablets	20	4	2	
	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	20	4	2	
Levothyroxine	Tablet containing 50 micrograms anhydrous levothyroxine sodium	20	200	1	
	Tablet containing 75 micrograms anhydrous levothyroxine sodium	20	200	1	
	Tablet containing 100 micrograms anhydrous levothyroxine sodium	20	200	1	
	Tablet containing 125 micrograms anhydrous levothyroxine sodium	20	200	1	
	Tablet containing 200 micrograms anhydrous levothyroxine sodium	20	200	1	
Linagliptin	Tablet 5 mg	20	30	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Linagliptin with metformin	Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride	20	60	5	
	Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride	20	60	5	
	Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride	20	60	5	
Liothyronine	Tablet containing liothyronine sodium 20 micrograms	20	100	2	
Lisinopril	Tablet 5 mg	20	30	5	
	Tablet 10 mg	20	30	5	
	Tablet 20 mg	20	30	5	
Medroxyprogesterone	Injection containing medroxyprogesterone acetate 150 mg in 1 mL pre-filled syringe	20	1	1	
	Tablet containing medroxyprogesterone acetate 5 mg	20	56	2	
	Tablet containing medroxyprogesterone acetate 10 mg	20	30	2	
		20	100	2	
Melatonin	Tablet 1 mg (modified release)	20	60	5	
	Tablet 5 mg (modified release)	20	30	5	
Meloxicam	Capsule 15 mg	20	30	3	
	Tablet 15 mg	20	30	3	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Memantine	Tablet containing memantine hydrochloride 10 mg	20	56	5	
	Tablet containing memantine hydrochloride 20 mg	20	28	5	
Mesalazine	Sachet containing granules, 500 mg per sachet	20	200	5	
	Sachet containing granules, 1 g per sachet	20	100	5	
	Sachet containing granules, 1.5 g per sachet	20	60	5	
	Sachet containing granules, 3 g per sachet	20	30	5	
	Sachet containing prolonged release granules, 1 g per sachet	20	100	5	
	Sachet containing prolonged release granules, 2 g per sachet	20	60	5	
	Sachet containing prolonged release granules, 4 g per sachet	20	30	5	
	Tablet 250 mg (enteric coated)	20	100	5	
	Tablet 500 mg (enteric coated)	20	200	5	
	Tablet 500 mg (prolonged release)	20	200	5	
	Tablet 800 mg (enteric coated)	20	90	5	
	Tablet 1 g (enteric coated)	20	120	5	
	Tablet 1 g (prolonged release)	20	120	5	
	Tablet 1.2 g (prolonged release)	20	120	5	
Tablet 1.6 g (enteric coated)	20	120	4		

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Metformin	Tablet containing metformin hydrochloride 500 mg	20	100	5	
	Tablet containing metformin hydrochloride 850 mg	20	60	5	
	Tablet containing metformin hydrochloride 1 g	20	90	5	
	Tablet (extended release) containing metformin hydrochloride 500 mg	20	120	5	
	Tablet (extended release) containing metformin hydrochloride 1 g	20	60	5	
Methadone	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL	20	840	5	
	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL	20	840	5	
Methotrexate	Injection 7.5 mg in 0.15 mL pre-filled syringe	20	4	5	
	Injection 10 mg in 0.2 mL pre-filled syringe	20	4	5	
	Injection 15 mg in 0.3 mL pre-filled syringe	20	4	5	
	Injection 20 mg in 0.4 mL pre-filled syringe	20	4	5	
	Injection 25 mg in 0.5 mL pre-filled syringe	20	4	5	
	Tablet 10 mg	20	10	5	
Methyldopa	Tablet 250 mg (as sesquihydrate)	20	100	5	
Methylprednisolone	Injection containing methylprednisolone acetate 40 mg in 1 mL	20	5	0	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Metoprolol	Tablet containing metoprolol tartrate 50 mg	20	100	5	
	Tablet containing metoprolol tartrate 100 mg	20	60	5	
Metoprolol succinate	Tablet 47.5 mg (controlled release)	20	30	5	
	Tablet 95 mg (controlled release)	20	30	5	
	Tablet 190 mg (controlled release)	20	30	5	
Migalastat	Capsule containing 150 mg migalastat hydrochloride (equivalent to 123 mg migalastat)	20	14	5	
Minocycline	Tablet 50 mg (as hydrochloride)	20	60	5	
Minoxidil	Tablet 10 mg	20	100	5	
Mirtazapine	Tablet 45 mg	20	30	5	
	Tablet 45 mg (orally disintegrating)	20	30	5	
Moclobemide	Tablet 150 mg	20	60	5	
	Tablet 300 mg	20	60	5	
Modafinil	Tablet 100 mg	20	120	5	
Momelotinib	Tablet 100 mg (as dihydrochloride monohydrate)	20	30	0	
		20	30	5	
	Tablet 150 mg (as dihydrochloride monohydrate)	20	30	0	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	30	5	
	Tablet 200 mg (as dihydrochloride monohydrate)	20	30	0	
		20	30	5	
Montelukast	Tablet, chewable, 4 mg (as sodium)	20	28	5	
	Tablet, chewable, 5 mg (as sodium)	20	28	5	
Moxonidine	Tablet 200 micrograms	20	30	5	
	Tablet 400 micrograms	20	30	5	
Nafarelin	Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses	20	1	5	
Naproxen	Tablet 750 mg (sustained release)	20	28	0	
		20	28	3	
	Tablet 1 g (sustained release)	20	28	0	
		20	28	3	
Nebivolol	Tablet 1.25 mg (as hydrochloride)	20	56	5	
	Tablet 5 mg (as hydrochloride)	20	28	5	
	Tablet 10 mg (as hydrochloride)	20	28	5	
Nicorandil	Tablets 10 mg, 60	20	1	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablets 20 mg, 60	20	1	5	
Nifedipine	Tablet 30 mg (controlled release)	20	30	5	
	Tablet 60 mg (controlled release)	20	30	5	
Nilotinib	Capsule 150 mg (as hydrochloride monohydrate)	20	120	5	
	Capsule 200 mg (as hydrochloride monohydrate)	20	120	5	
Nintedanib	Capsule 100 mg	20	60	5	
	Capsule 150 mg	20	60	5	
Niraparib	Tablet 100 mg (as tosilate monohydrate)	20	56	2	
		20	56	5	
		20	84	2	
		20	84	5	
Nizatidine	Capsule 150 mg	20	60	5	
	Capsule 300 mg	20	30	5	
Norethisterone	Tablets 350 micrograms, 28	20	4	2	
Norethisterone with ethinylestradiol	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	20	4	2	
	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	20	4	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Obeticholic acid	Tablet 5 mg	20	30	5	
	Tablet 10 mg	20	30	5	
Ofatumumab	Solution for injection 20 mg in 0.4 mL pre-filled pen	20	1	5	
		20	3	0	
Olaparib	Tablet 100 mg	20	112	5	
		20	112	6	
	Tablet 150 mg	20	112	5	
		20	112	6	
Olmesartan	Tablet containing olmesartan medoxomil 20 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg	20	30	5	
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	20	30	5	
Olmesartan with amlodipine and hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	5 mg (as besilate) and hydrochlorothiazide 12.5 mg				
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg	20	30	5	
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	20	30	5	
	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	20	30	5	
Olsalazine	Capsule containing olsalazine sodium 250 mg	20	100	5	
	Tablet containing olsalazine sodium 500 mg	20	100	5	
Omeprazole	Capsule 20 mg	20	30	1	
		20	30	5	
		20	60	5	
	Tablet 10 mg (as magnesium)	20	30	5	
	Tablet 20 mg	20	30	1	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	30	5	
		20	60	5	
	Tablet 20 mg (as magnesium)	20	30	1	
		20	30	5	
		20	60	5	
Opicapone	Capsule 50 mg	20	30	5	
Oxcarbazepine	Tablet 600 mg	20	100	5	
Oxybutynin	Tablet containing oxybutynin hydrochloride 5 mg	20	100	5	
	Transdermal patches 36 mg, 8	20	1	5	
Ozanimod	Capsule 920 micrograms	20	28	3	
		20	28	5	
	Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms	20	1	0	
Palbociclib	Tablet 75 mg	20	21	5	
	Tablet 100 mg	20	21	5	
	Tablet 125 mg	20	21	5	
Pantoprazole	Sachet containing granules 40 mg (as sodium sesquihydrate)	20	30	1	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	30	5	
		20	60	5	
	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	20	30	5	
	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	20	30	1	
		20	30	5	
		20	60	5	
Paracetamol	Tablet 500 mg	20	300	0	
	Tablet 665 mg (modified release)	20	192	5	
Paroxetine	Tablet 20 mg (as hydrochloride)	20	30	5	
Patiromer	Powder for oral suspension 8.4 g	20	30	5	
	Powder for oral suspension 16.8 g	20	30	5	
Pazopanib	Tablet 200 mg (as hydrochloride)	20	30	5	
		20	90	2	
		20	90	5	
	Tablet 400 mg (as hydrochloride)	20	30	5	
		20	60	2	
		20	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Perampanel	Tablet 4 mg (as hemisesquihydrate)	20	28	5	
	Tablet 6 mg (as hemisesquihydrate)	20	28	5	
	Tablet 8 mg (as hemisesquihydrate)	20	28	5	
	Tablet 10 mg (as hemisesquihydrate)	20	28	5	
	Tablet 12 mg (as hemisesquihydrate)	20	28	5	
Perhexiline	Tablet containing perhexiline maleate 100 mg	20	100	5	
Perindopril	Tablet containing perindopril arginine 2.5 mg	20	30	5	
	Tablet containing perindopril arginine 5 mg	20	30	5	
	Tablet containing perindopril arginine 10 mg	20	30	5	
	Tablet containing perindopril erbumine 2 mg	20	30	5	
	Tablet containing perindopril erbumine 4 mg	20	30	5	
	Tablet containing perindopril erbumine 8 mg	20	30	5	
Perindopril with amlodipine	Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate)	20	30	5	
	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)	20	30	5	
	Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate)	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate)	20	30	5	
Perindopril with indapamide	Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg	20	30	5	
	Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg	20	30	5	
	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	20	30	5	
Phenobarbital	Tablet 30 mg	20	200	4	
Phenoxybenzamine	Capsule containing phenoxybenzamine hydrochloride 10 mg	20	100	5	
Phenytoin	Capsule containing phenytoin sodium 30 mg	20	200	2	
	Capsule containing phenytoin sodium 100 mg	20	200	2	
	Tablet 50 mg	20	200	2	
Pioglitazone	Tablet 45 mg (as hydrochloride)	20	28	5	
Pirfenidone	Tablet 267 mg	20	270	5	
	Tablet 801 mg	20	90	5	
Pizotifen	Tablet 500 micrograms (as malate)	20	100	2	
Ponatinib	Tablet 15 mg (as hydrochloride)	20	60	2	
		20	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 45 mg (as hydrochloride)	20	30	2	
		20	30	5	
Potassium chloride	Tablet 600 mg (sustained release)	20	200	1	
Potassium chloride with potassium bicarbonate	Tablet, effervescent, 14 mmol potassium and 8 mmol chloride	20	60	1	
Pramipexole	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg	20	30	5	
		20	30	5	
		20	30	5	
		20	30	5	
		20	30	5	
Prasugrel	Tablet 5 mg	20	28	5	
		20	28	5	
Pravastatin	Tablet containing pravastatin sodium 10 mg	20	30	5	
		20	30	5	
		20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Prazosin	Tablet containing pravastatin sodium 80 mg	20	30	5	
	Capsule 1 mg (as hydrochloride) (S19A)	20	100	5	
	Tablet 1 mg (as hydrochloride)	20	100	5	
	Tablet 2 mg (as hydrochloride)	20	100	5	
	Tablet 5 mg (as hydrochloride)	20	100	5	
Pregabalin	Capsule 300 mg	20	56	5	
Primidone	Tablet 250 mg	20	200	2	
Probenecid	Tablet 500 mg	20	100	5	
Progesterone	Capsule 100 mg	20	30	5	
Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	20	1	5	
Proprantheline	Tablet containing proprantheline bromide 15 mg	20	200	5	
Propranolol	Tablet containing propranolol hydrochloride 10 mg	20	100	5	
	Tablet containing propranolol hydrochloride 40 mg	20	100	5	
Quinagolide	Tablet 75 micrograms (as hydrochloride)	20	30	5	
Quinapril	Tablet 5 mg (as hydrochloride)	20	30	5	
	Tablet 10 mg (as hydrochloride)	20	30	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 20 mg (as hydrochloride)	20	30	5	
Quinapril with hydrochlorothiazide	Tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide	20	30	5	
	Tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide	20	30	5	
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	20	28	5	
	Tablet containing rabeprazole sodium 20 mg (enteric coated)	20	30	1	
		20	30	5	
		20	60	5	
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	20	28	5	
Raltegravir	Tablet 600 mg (as potassium)	20	120	5	
Ramipril	Capsule 1.25 mg	20	30	5	
	Capsule 2.5 mg	20	30	5	
	Capsule 5 mg	20	30	5	
	Capsule 10 mg	20	30	5	
	Tablet 1.25 mg	20	30	5	
	Tablet 2.5 mg	20	30	5	
	Tablet 5 mg	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 10 mg	20	30	5	
Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	20	30	5	
	Tablet 5 mg-5 mg (modified release)	20	30	5	
Ranitidine	Tablet 150 mg (as hydrochloride)	20	60	5	
	Tablet 300 mg (as hydrochloride)	20	30	5	
Rasagiline	Tablet 1 mg (as mesilate)	20	30	5	
Reboxetine	Tablet 4 mg (as mesilate)	20	60	5	
Relugolix with estradiol and with norethisterone	Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 500 micrograms	20	28	5	
Ribociclib	Tablet 200 mg	20	21	5	
		20	42	5	
		20	63	5	
Rifaximin	Tablet 550 mg	20	56	5	
Riluzole	Tablet 50 mg	20	56	5	
Ripretinib	Tablet 50 mg	20	90	1	
Risankizumab	Injection 150 mg in 1 mL pre-filled pen	20	1	1	
		20	1	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Risedronic acid	Tablet containing risedronate sodium 5 mg	20	28	5	
	Tablet containing risedronate sodium 30 mg	20	28	1	
	Tablet containing risedronate sodium 35 mg	20	4	5	
	Tablet containing risedronate sodium 150 mg	20	1	5	
	Tablet (enteric coated) containing risedronate sodium 35 mg	20	4	5	
Rivaroxaban	Tablet 2.5 mg	20	60	5	
	Tablet 10 mg	20	30	5	
	Tablet 15 mg	20	28	5	
	Tablet 20 mg	20	28	5	
Rivastigmine	Capsule 1.5 mg (as hydrogen tartrate)	20	56	5	
	Capsule 3 mg (as hydrogen tartrate)	20	56	5	
	Capsule 4.5 mg (as hydrogen tartrate)	20	56	5	
	Capsule 6 mg (as hydrogen tartrate)	20	56	5	
	Transdermal patch 9 mg	20	30	5	
	Transdermal patch 18 mg	20	30	5	
	Transdermal patch 27 mg	20	30	5	
Romosozumab	Injection 105 mg in 1.17 mL single use pre-filled syringe	20	2	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Rosuvastatin	Tablet 5 mg (as calcium)	20	30	5	
	Tablet 10 mg (as calcium)	20	30	5	
	Tablet 20 mg (as calcium)	20	30	5	
	Tablet 40 mg (as calcium)	20	30	5	
Rotigotine	Transdermal patch 4.5 mg	20	28	5	
	Transdermal patch 9 mg	20	28	5	
	Transdermal patch 13.5 mg	20	28	5	
	Transdermal patch 18 mg	20	28	5	
Ruxolitinib	Tablet 5 mg	20	56	5	
		20	112	0	
	Tablet 10 mg	20	112	5	
		20	56	0	
	Tablet 15 mg	20	56	5	
		20	56	0	
	Tablet 20 mg	20	56	5	
		20	56	0	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Sacubitril with valsartan	Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg	20	56	5	
	Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg	20	56	5	
	Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg	20	56	5	
Safinamide	Tablet 50 mg	20	30	5	
	Tablet 100 mg	20	30	5	
Sapropterin	Powder for oral solution 500 mg (as dihydrochloride)	20	30	5	
	Tablet (soluble) containing sapropterin dihydrochloride 100 mg	20	180	5	
Saxagliptin	Tablet 2.5 mg (as hydrochloride)	20	28	5	
	Tablet 5 mg (as hydrochloride)	20	28	5	
Saxagliptin with dapagliflozin	Tablet containing saxagliptin 5 mg with dapagliflozin 10 mg	20	28	5	
Saxagliptin with metformin	Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride	20	56	5	
	Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride	20	28	5	
	Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride	20	28	5	
Secukinumab	Injection 150 mg in 1 mL pre-filled pen	20	1	5	
		20	2	3	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	2	5	
		20	8	0	
Selegiline	Tablet containing selegiline hydrochloride 5 mg	20	100	5	
Selpercatinib	Capsule 40 mg	20	56	5	
	Capsule 80 mg	20	112	5	
Selumetinib	Capsule 10 mg	20	60	5	
	Capsule 25 mg	20	60	5	
Sertraline	Tablet 50 mg (as hydrochloride)	20	30	5	
	Tablet 100 mg (as hydrochloride)	20	30	5	
Sevelamer	Tablet containing sevelamer carbonate 800 mg	20	180	5	
	Tablet containing sevelamer hydrochloride 800 mg	20	180	5	
Simvastatin	Tablet 5 mg	20	30	5	
	Tablet 10 mg	20	30	5	
	Tablet 20 mg	20	30	5	
	Tablet 40 mg	20	30	5	
	Tablet 80 mg	20	30	5	
Siponimod	Tablet 250 micrograms (as hemifumarate)	20	120	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Sitagliptin	Tablet 1 mg (as hemifumarate)	20	28	5	
	Tablet 2 mg (as hemifumarate)	20	28	5	
	Tablet 25 mg	20	28	5	
	Tablet 50 mg	20	28	5	
	Tablet 100 mg	20	28	5	
Sitagliptin with metformin	Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride	20	56	5	
	Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride	20	56	5	
	Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride	20	56	5	
	Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride	20	56	5	
	Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride	20	28	5	
Sonidegib	Capsule 200 mg	20	30	3	
Sorafenib	Tablet 200 mg (as tosilate)	20	120	2	
		20	120	5	
Spirolactone	Tablet 25 mg	20	100	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Sulfasalazine	Tablet 100 mg	20	100	5	
	Tablet 500 mg	20	200	5	
	Tablet 500 mg (enteric coated)	20	200	5	
Sulthiame	Tablet 50 mg	20	200	2	
	Tablet 200 mg	20	200	2	
Sunitinib	Capsule 12.5 mg	20	28	1	
		20	28	2	
		20	28	3	
		20	28	5	
	Capsule 25 mg	20	28	1	
		20	28	2	
		20	28	3	
		20	28	5	
	Capsule 37.5 mg	20	28	1	
		20	28	2	
		20	28	3	
		20	28	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Capsule 50 mg	20	28	1	
		20	28	2	
		20	28	3	
		20	28	5	
Tafamidis	Capsule 61 mg	20	30	5	
Talazoparib	Capsule 100 micrograms (as tosilate)	20	30	5	
	Capsule 250 micrograms (as tosilate)	20	30	5	
	Capsule 350 micrograms (as tosilate)	20	30	5	
	Capsule 500 micrograms (as tosilate)	20	30	5	
Tamoxifen	Tablet 20 mg (as citrate)	20	30	5	
		20	60	5	
Teduglutide	Powder for injection 5 mg with diluent	20	28	0	
		20	28	5	
		20	28	11	
Telmisartan	Tablet 40 mg	20	28	5	
	Tablet 80 mg	20	28	5	
Telmisartan with amlodipine	Tablet 40 mg-5 mg (as besilate)	20	28	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Telmisartan with hydrochlorothiazide	Tablet 40 mg-10 mg (as besilate)	20	28	5	
	Tablet 80 mg-5 mg (as besilate)	20	28	5	
	Tablet 80 mg-10 mg (as besilate)	20	28	5	
	Tablet 40 mg-12.5 mg	20	28	5	
	Tablet 80 mg-12.5 mg	20	28	5	
	Tablet 80 mg-25 mg	20	28	5	
Temozolomide	Capsule 5 mg	20	5	5	
		20	15	2	
	Capsule 20 mg	20	5	5	
		20	15	2	
	Capsule 100 mg	20	5	5	
		20	15	2	
	Capsule 140 mg	20	5	5	
		20	15	2	
	Capsule 180 mg	20	5	5	
Capsule 250 mg	20	5	5		

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat	Tablet containing tenofovir alafenamide 10 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg	20	60	5	
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	20	30	2	
	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	20	30	2	
Terbinafine	Tablet 250 mg (as hydrochloride)	20	42	0	
		20	42	1	
Teriflunomide	Tablet 14 mg	20	28	5	
Teriparatide	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	20	1	5	
Testosterone	I.M. injection containing testosterone undecanoate 1,000 mg in 4 mL	20	1	1	
	Transdermal cream 50 mg per mL, 50 mL	20	1	1	
	Transdermal gel 50 mg in 5 g sachet, 30	20	1	5	
	Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2	20	1	4	
	Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses	20	1	5	
Tetrabenazine	Tablet 25 mg	20	112	5	
Theophylline	Tablet 200 mg (sustained release)	20	100	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Tiagabine	Tablet 250 mg (sustained release)	20	100	5	
	Tablet 300 mg (sustained release)	20	100	5	
	Tablet 5 mg (as hydrochloride)	20	100	5	
	Tablet 10 mg (as hydrochloride)	20	100	5	
	Tablet 15 mg (as hydrochloride)	20	100	5	
Ticagrelor	Tablet 90 mg	20	56	5	
Tiotropium	Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device)	20	30	5	
	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler)	20	30	5	
	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler)	20	30	5	
	Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)	20	1	5	
Tiotropium with olodaterol	Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses	20	1	5	
Tocilizumab	Injection 162 mg in 0.9 mL single use pre-filled pen	20	4	5	
		20	4	6	
	Injection 162 mg in 0.9 mL single use pre-filled syringe	20	4	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Tofacitinib	Tablet 5 mg	20	4	6	
		20	56	3	
	Tablet 10 mg	20	56	5	
		20	56	3	
Topiramate	Capsule 15 mg	20	56	5	
		20	60	5	
	Capsule 25 mg	20	60	5	
		20	60	5	
	Capsule 50 mg	20	60	5	
		20	60	5	
	Tablet 25 mg	20	60	5	
		20	60	5	
Trandolapril	Tablet 50 mg	20	60	5	
		20	60	5	
	Tablet 100 mg	20	60	5	
		20	60	5	
Trandolapril with verapamil	Capsule 500 micrograms	20	28	5	
		20	28	5	
	Capsule 1 mg	20	28	5	
		20	28	5	
Capsule 2 mg	20	28	5		
	20	28	5		
Capsule 4 mg	20	28	5		
	20	28	5		
Trandolapril with verapamil	Tablet containing trandolapril 2 mg with verapamil hydrochloride	20	28	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	180 mg (sustained release)				
	Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release)	20	28	5	
Triamcinolone	Injection containing triamcinolone acetonide 10 mg in 1 mL	20	5	0	
Trientine	Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine)	20	200	5	
Trihexyphenidyl	Tablet containing trihexyphenidyl hydrochloride 2 mg	20	200	2	
	Tablet containing trihexyphenidyl hydrochloride 5 mg	20	200	1	
Triptorelin	Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles	20	1	5	
	Powder for I.M. injection (prolonged release) 11.25 mg (as embonate) with solvent, syringe and needles	20	1	1	
	Powder for I.M. injection (prolonged release) 22.5 mg (as embonate) with solvent, syringe and needles	20	1	0	
Umeclidinium	Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses	20	1	5	
Umeclidinium with vilanterol	Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenate) per dose, 30 doses	20	1	5	
Upadacitinib	Tablet 15 mg	20	28	1	
		20	28	3	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		20	28	4	
		20	28	5	
	Tablet 30 mg	20	28	1	
		20	28	2	
		20	28	3	
		20	28	4	
		20	28	5	
	Tablet 45 mg	20	28	2	
		20	28	3	
Ustekinumab	Injection 45 mg in 0.5 mL	20	1	0	
		20	1	1	
		20	1	2	
		20	2	0	
Valaciclovir	Tablet 500 mg (as hydrochloride)	20	30	5	
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	20	200	2	
	Tablet (enteric coated) containing sodium valproate 500 mg	20	200	2	
Valsartan	Tablet 80 mg	20	28	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Valsartan with hydrochlorothiazide	Tablet 160 mg	20	28	5	
	Tablet 320 mg	20	28	5	
	Tablet 80 mg-12.5 mg	20	28	5	
	Tablet 160 mg-12.5 mg	20	28	5	
	Tablet 160 mg-25 mg	20	28	5	
	Tablet 320 mg-12.5 mg	20	28	5	
	Tablet 320 mg-25 mg	20	28	5	
Varenicline	Box containing 11 tablets 0.5 mg and 42 tablets 1 mg	20	1	0	
	Tablet 1 mg	20	56	2	
		20	112	0	
Vedolizumab	Injection 108 mg in 0.68 mL single use pre-filled pen	20	2	0	
		20	2	5	
Venetoclax	Tablet 100 mg	20	120	2	
		20	120	4	
		20	120	5	
Venlafaxine	Capsule (modified release) 75 mg (as hydrochloride)	20	28	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply **Schedule 1**

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Verapamil	Capsule (modified release) 150 mg (as hydrochloride)	20	28	5	
	Tablet containing verapamil hydrochloride 80 mg	20	100	5	
	Tablet containing verapamil hydrochloride 180 mg (sustained release)	20	30	5	
Vigabatrin	Tablet containing verapamil hydrochloride 240 mg (sustained release)	20	30	5	
	Oral powder, sachet 500 mg	20	60	5	
Vildagliptin	Tablet 500 mg	20	100	5	
	Tablet 50 mg	20	60	5	
Vildagliptin with metformin	Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride	20	60	5	
	Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride	20	60	5	
	Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride	20	60	5	
Vismodegib	Capsule 150 mg	20	28	3	
Vosoritide	Powder for injection 400 micrograms with diluent	20	30	5	
	Powder for injection 560 micrograms with diluent	20	30	5	
	Powder for injection 1.2 mg with diluent	20	30	5	

Schedule 1 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Zanubrutinib	Capsule 80 mg	20	120	5	
Zonisamide	Capsule 25 mg	20	56	5	
	Capsule 50 mg	20	56	5	
	Capsule 100 mg	20	112	5	

Schedule 2—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Acarbose	Tablet 50 mg	50	180	5	
	Tablet 50 mg (S19A)	50	180	5	
	Tablet 100 mg	50	180	5	
	Tablet 100 mg (S19A)	50	180	5	
Acidinium	Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses	50	2	5	
Acidinium with formoterol	Powder for oral inhalation in breath actuated device containing acidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses	50	2	5	
Adapalene with benzoyl peroxide	Gel 1 mg-25 mg per g, 30 g	50	2	3	
Alendronic acid	Tablet 70 mg (as alendronate sodium)	50	8	5	
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	50	8	5	
	Tablet 70 mg (as alendronate sodium) with 140 micrograms	50	8	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	coleciferol				
Allopurinol	Tablet 100 mg	50	400	2	
	Tablet 300 mg	50	120	2	
Alogliptin	Tablet 6.25 mg (as benzoate)	50	56	5	
	Tablet 12.5 mg (as benzoate)	50	56	5	
	Tablet 25 mg (as benzoate)	50	56	5	
Alogliptin with metformin	Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride	50	112	5	
	Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride	50	112	5	
	Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride	50	112	5	
Amantadine	Capsule containing amantadine hydrochloride 100 mg	50	200	5	
Amlodipine	Tablet 5 mg (as besilate)	50	60	5	
	Tablet 10 mg (as besilate)	50	60	5	
Amlodipine with atorvastatin	Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)	50	60	5	
	Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)	50	60	5	
	Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)	50	60	5	
	Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)	50	60	5	
	Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)	50	60	5	
	Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)	50	60	5	
	Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)	50	60	5	
Amlodipine with valsartan	Tablet 5 mg (as besilate)-80 mg	50	56	5	
	Tablet 5 mg (as besilate)-160 mg	50	56	5	
	Tablet 5 mg (as besilate)-320 mg	50	56	5	
	Tablet 10 mg (as besilate)-160 mg	50	56	5	
	Tablet 10 mg (as besilate)-320 mg	50	56	5	
Amlodipine with valsartan and hydrochlorothiazide	Tablet 5 mg (as besilate)-160 mg-12.5 mg	50	56	5	
	Tablet 5 mg (as besilate)-160 mg-25 mg	50	56	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 10 mg (as besilate)-160 mg-12.5 mg	50	56	5	
	Tablet 10 mg (as besilate)-160 mg-25 mg	50	56	5	
	Tablet 10 mg (as besilate)-320 mg-25 mg	50	56	5	
Anastrozole	Tablet 1 mg	50	60	5	
Apixaban	Tablet 2.5 mg	50	120	5	
	Tablet 5 mg	50	120	5	
Apomorphine	Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL	50	360	5	
	Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL	50	180	5	
	Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe	50	360	5	
	Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen	50	200	5	
Atenolol	Oral solution 50 mg in 10 mL, 300 mL	50	2	5	
	Tablet 50 mg	50	60	5	
Atorvastatin	Tablet 10 mg (as calcium)	50	60	5	
	Tablet 20 mg (as calcium)	50	60	5	
	Tablet 40 mg (as calcium)	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Baclofen	Tablet 80 mg (as calcium)	50	60	5	
	Tablet 10 mg	50	200	5	
	Tablet 25 mg	50	200	5	
Balsalazide	Capsule containing balsalazide sodium 750 mg	50	560	5	
Beclometasone	Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)	50	2	5	
Beclometasone with formoterol	Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose	50	2	5	
	Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses	50	2	5	
Beclometasone with formoterol and glycopyrronium	Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	doses				
Betaxolol	Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL	50	2	5	
Bimatoprost	Eye drops 300 micrograms per mL, 3 mL	50	2	5	
	Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30	50	2	5	
Bimatoprost with timolol	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL	50	2	5	
	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30	50	2	5	
Bisacodyl	Suppositories 10 mg, 10	50	6	5	
	Suppositories 10 mg, 12	50	6	4	
	Tablet 5 mg	50	400	2	
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	50	56	5	
	Tablet containing bisoprolol fumarate 5 mg	50	56	5	
	Tablet containing bisoprolol fumarate 10 mg	50	56	5	
Brimonidine	Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL	50	2	5	
	Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL	50	2	5	
Brimonidine with timolol	Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL	50	2	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply– increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Brinzolamide	Eye drops 10 mg per mL, 5 mL	50	2	5	
Brinzolamide with brimonidine	Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL	50	2	5	
Brinzolamide with timolol	Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL	50	2	5	
Bromocriptine	Tablet 2.5 mg (as mesilate)	50	120	5	
Budesonide	Nebuliser suspension 1 mg in 2 mL single dose units, 30	50	2	5	
	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	50	2	5	
	Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses	50	2	5	
	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	50	2	5	
	Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses	50	2	5	
Budesonide with formoterol	Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses	50	4	5	
	Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses	50	4	5	
	Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses	50	4	5	
Budesonide with glycopyrronium and formoterol	Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses	50	2	5	
Cabergoline	Tablet 500 micrograms	50	16	5	
	Tablet 1 mg	50	60	5	
	Tablet 2 mg	50	60	5	
Calcipotriol with betamethasone	Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g	50	2	1	
	Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g	50	2	1	
Calcitriol	Capsule 0.25 microgram	50	200	3	
Calcium	Tablet, chewable, 500 mg (as carbonate)	50	480	1	
	Tablet 600 mg (as carbonate)	50	480	1	
Candesartan	Tablet containing candesartan cilexetil 4 mg	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Candesartan with hydrochlorothiazide	Tablet containing candesartan cilexetil 8 mg	50	60	5	
	Tablet containing candesartan cilexetil 16 mg	50	60	5	
	Tablet containing candesartan cilexetil 32 mg	50	60	5	
	Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg	50	60	5	
	Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg	50	60	5	
Carbamazepine	Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg	50	60	5	
	Oral suspension 100 mg per 5 mL, 300 mL	50	2	5	
	Tablet 100 mg	50	400	2	
	Tablet 200 mg	50	400	2	
	Tablet 200 mg (controlled release)	50	400	2	
Carbimazole	Tablet 400 mg (controlled release)	50	400	2	
	Tablet 5 mg	50	400	2	
Carbomer	Eye gel 2 mg per g, 10 g	50	2	5	
	Eye gel 2 mg per g, single dose units 0.6 mL, 30	50	6	5	
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 10 mL	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Carvedilol	Tablet 6.25 mg	50	120	5	
	Tablet 12.5 mg	50	120	5	
	Tablet 25 mg	50	120	5	
Chlortalidone	Tablet 25 mg	50	200	1	
Ciclesonide	Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation)	50	2	5	
Ciclosporin	Capsule 10 mg	50	240	3	
	Capsule 25 mg	50	120	3	
	Capsule 50 mg	50	120	3	
	Capsule 100 mg	50	120	3	
	Oral liquid 100 mg per mL, 50 mL	50	4	3	
Citalopram	Tablet 10 mg (as hydrobromide)	50	56	2	
	Tablet 20 mg (as hydrobromide)	50	56	2	
	Tablet 40 mg (as hydrobromide)	50	56	2	
Clonidine	Tablet containing clonidine hydrochloride 100 micrograms	50	200	5	
	Tablet containing clonidine hydrochloride 150 micrograms	50	200	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Clopidogrel	Tablet 75 mg (as besilate)	50	56	5	
	Tablet 75 mg (as hydrogen sulfate)	50	56	5	
Clopidogrel with aspirin	Tablet 75 mg (as hydrogen sulfate)-100 mg	50	60	5	
Colestyramine	Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50	50	4	5	
Cortisone	Tablet containing cortisone acetate 5 mg	50	100	4	
	Tablet containing cortisone acetate 25 mg	50	120	4	
Cyproterone	Tablet containing cyproterone acetate 50 mg	50	40	5	
		50	200	5	
	Tablet containing cyproterone acetate 100 mg	50	100	5	
Dabigatran etexilate	Capsule 110 mg (as mesilate)	50	120	5	
	Capsule 150 mg (as mesilate)	50	120	5	
Dapagliflozin	Tablet 10 mg (as propanediol monohydrate)	50	56	5	
Dapagliflozin with metformin	Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride	50	112	5	
	Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride	50	56	5	
	Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride	50	56	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Dapagliflozin with sitagliptin	Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate)	50	56	5	
Desmopressin	Tablet containing desmopressin acetate 200 micrograms	50	60	5	
		50	180	5	
	Wafer 120 micrograms (as acetate)	50	60	5	
	Wafer 240 micrograms (as acetate)	50	60	5	
Desvenlafaxine	Tablet (extended release) 100 mg (as succinate)	50	56	2	
	Tablet (extended release) 50 mg (as succinate)	50	56	2	
	Tablet (modified release) 100 mg	50	56	2	
	Tablet (modified release) 100 mg (as benzoate)	50	56	2	
	Tablet (modified release) 50 mg	50	56	2	
	Tablet (modified release) 50 mg (as benzoate)	50	56	2	
Dexamethasone	Tablet 500 micrograms	50	60	4	
Diltiazem	Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg	50	60	5	
	Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg	50	60	5	
	Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet containing diltiazem hydrochloride 60 mg	50	180	5	
Dorzolamide	Eye drops 20 mg (as hydrochloride) per mL, 5 mL	50	2	5	
Dorzolamide with timolol	Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL	50	2	5	
Doxycycline	Capsule 100 mg (as hyclate) (containing enteric coated pellets)	50	56	2	
	Capsule 50 mg (as hyclate) (containing enteric coated pellets)	50	50	2	
	Tablet 100 mg (as hyclate)	50	56	2	
	Tablet 100 mg (as monohydrate)	50	56	2	
	Tablet 50 mg (as hyclate)	50	50	2	
	Tablet 50 mg (as monohydrate)	50	50	2	
Duloxetine	Capsule 60 mg (as hydrochloride)	50	56	2	
Dutasteride	Capsule 500 micrograms	50	60	5	
Dutasteride with tamsulosin	Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms	50	60	5	
Empagliflozin	Tablet 10 mg	50	60	5	
	Tablet 25 mg	50	60	5	
Empagliflozin with linagliptin	Tablet containing 10 mg empagliflozin with 5 mg linagliptin	50	60	5	
	Tablet containing 25 mg empagliflozin with 5 mg linagliptin	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Empagliflozin with metformin	Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride	50	120	5	
	Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride	50	120	5	
	Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride	50	120	5	
	Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride	50	120	5	
Enalapril	Tablet containing enalapril maleate 5 mg	50	60	5	
	Tablet containing enalapril maleate 10 mg	50	60	5	
	Tablet containing enalapril maleate 20 mg	50	60	5	
Enalapril with hydrochlorothiazide	Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg	50	60	5	
Entacapone	Tablet 200 mg	50	400	4	
Eplerenone	Tablet 25 mg	50	60	5	
	Tablet 50 mg	50	60	5	
Eprosartan	Tablet 600 mg (as mesilate)	50	56	5	
Eprosartan with hydrochlorothiazide	Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide	50	56	5	
Erythromycin	Capsule 250 mg (containing enteric coated pellets)	50	100	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Escitalopram	Oral solution 20 mg (as oxalate) per mL, 15 mL	50	2	2	
	Tablet 10 mg (as oxalate)	50	56	2	
	Tablet 20 mg (as oxalate)	50	56	2	
Esomeprazole	Capsule (enteric) 20 mg (as magnesium)	50	60	5	
		50	120	5	
	Capsule (enteric) 40 mg (as magnesium)	50	60	5	
		50	120	5	
		50	120	5	
	Tablet (enteric coated) 20 mg (as magnesium)	50	60	5	
		50	120	5	
50		120	5		
Estradiol	Pessary (modified release) 10 micrograms (as hemihydrate)	50	36	2	
	Tablet 2 mg	50	112	2	
	Tablet containing estradiol valerate 1 mg	50	112	2	
	Tablet containing estradiol valerate 2 mg	50	112	2	
	Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Estradiol and estradiol with dydrogesterone	Transdermal gel 500 micrograms in 0.5 g sachet, 28	50	2	5	
	Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28	50	2	5	
	Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg	50	2	5	
	Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg	50	2	5	
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate	50	2	5	
	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate	50	2	5	
Estradiol with norethisterone	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8	50	2	5	
	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)	50	2	5	
	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8	50	2	5	
	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)	50	2	5	
Estriol	Pessaries 500 micrograms, 15	50	2	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Vaginal cream 1 mg per g, 15 g	50	2	1	
Ethosuximide	Oral solution 250 mg per 5 mL, 200 mL	50	2	5	
Everolimus	Tablet 0.75 mg	50	240	3	
	Tablet 1 mg	50	240	3	
Exemestane	Tablet 25 mg	50	60	5	
Ezetimibe	Tablet 10 mg	50	60	5	
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)	50	2	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)	50	2	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)	50	2	5	
	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)	50	2	5	
Ezetimibe with atorvastatin	Tablet 10 mg-10 mg	50	60	5	
	Tablet 10 mg-20 mg	50	60	5	
	Tablet 10 mg-40 mg	50	60	5	
	Tablet 10 mg-80 mg	50	60	5	
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 10 mg-20 mg	50	60	5	
	Tablet 10 mg-40 mg	50	60	5	
	Tablet 10 mg-80 mg	50	60	5	
Febuxostat	Tablet 80 mg	50	56	5	
Felodipine	Tablet 2.5 mg (extended release)	50	60	5	
	Tablet 5 mg (extended release)	50	60	5	
	Tablet 10 mg (extended release)	50	60	5	
Fenofibrate	Tablet 48 mg	50	120	5	
	Tablet 145 mg	50	60	5	
Fluoxetine	Capsule 20 mg (as hydrochloride)	50	56	2	
	Tablet, dispersible, 20 mg (as hydrochloride)	50	56	2	
Fluticasone furoate	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses	50	2	5	
Fluticasone furoate with umeclidinium and vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenate) per dose, 30 doses	50	2	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Fluticasone furoate with vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenate) per dose, 30 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenate) per dose, 30 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenate) per dose, 30 doses	50	2	5	
Fluticasone propionate	Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses	50	2	5	
	Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation)	50	2	5	
Fluticasone propionate with formoterol	Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses	50	2	5	
	Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Fluticasone propionate with salmeterol	Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses	50	2	5	
	Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	50	2	5	
	Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)	50	2	5	
Fluvastatin	Tablet (prolonged release) 80 mg (as sodium)	50	56	5	
Fluvoxamine	Tablet containing fluvoxamine maleate 100 mg	50	60	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Formoterol	Tablet containing fluvoxamine maleate 50 mg	50	60	2	
	Capsule containing powder for oral inhalation containing formoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer)	50	120	5	
	Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses	50	2	5	
	Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses	50	2	5	
Furosemide	Oral solution 10 mg per mL, 30 mL	50	2	3	
	Tablet 20 mg	50	200	1	
	Tablet 40 mg	50	200	1	
	Tablet 500 mg	50	100	3	
Gemfibrozil	Tablet 600 mg	50	120	5	
Glibenclamide	Tablet 5 mg	50	200	5	
Gliclazide	Tablet 30 mg (modified release)	50	200	5	
	Tablet 60 mg (modified release)	50	120	5	
	Tablet 80 mg	50	200	5	
Glimepiride	Tablet 1 mg	50	60	5	
	Tablet 2 mg	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Glipizide	Tablet 3 mg	50	60	5	
	Tablet 4 mg	50	60	5	
	Tablet 5 mg	50	200	5	
Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	50	2	5	
	Transdermal patch 18 mg	50	60	5	
	Transdermal patch 25 mg	50	60	5	
	Transdermal patch 36 mg	50	60	5	
	Transdermal patch 50 mg	50	60	5	
	Transdermal patch 54 mg	50	60	5	
	Glycopyrronium	Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler)	50	60	5
Hyaluronic acid	Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL	50	2	5	
	Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL	50	2	5	
Hydrochlorothiazide	Tablet 25 mg	50	200	1	
Hydrochlorothiazide with amiloride	Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg	50	200	1	
Hydrocortisone	Tablet 4 mg	50	100	4	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 20 mg	50	120	4	
Hypromellose	0.3% w/v eye drops, 10 mL (preservative free)	50	2	5	
	Eye drops 3 mg per mL, 10 mL	50	2	5	
	Eye drops 5 mg per mL, 15 mL	50	2	5	
Hypromellose with dextran	Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL	50	2	5	
Indacaterol	Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler)	50	60	5	
	Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler)	50	60	5	
Indacaterol with glycopyrronium	Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler)	50	60	5	
Indacaterol with glycopyrronium and mometasone	Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler)	50	60	5	
	Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler)	50	60	5	
Indacaterol with mometasone	Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	127.5 micrograms (for use in Breezhaler)				
	Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler)	50	60	5	
	Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler)	50	60	5	
Indapamide	Tablet containing indapamide hemihydrate 1.5 mg (sustained release)	50	180	1	
	Tablet containing indapamide hemihydrate 2.5 mg	50	180	1	
Irbesartan	Tablet 75 mg	50	60	5	
	Tablet 150 mg	50	60	5	
	Tablet 300 mg	50	60	5	
Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	50	60	5	
	Tablet 300 mg-12.5 mg	50	60	5	
	Tablet 300 mg-25 mg	50	60	5	
Isosorbide dinitrate	Tablet 5 mg (sublingual)	50	400	2	
Isosorbide mononitrate	Tablet 60 mg (sustained release)	50	60	5	
	Tablet 120 mg (sustained release)	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Labetalol	Tablet containing labetalol hydrochloride 100 mg	50	200	5	
Lacosamide	Oral solution 10 mg per mL, 200 mL	50	4	5	
		50	12	5	
	Tablet 50 mg	50	112	5	
	Tablet 100 mg	50	112	5	
	Tablet 150 mg	50	112	5	
	Tablet 200 mg	50	112	5	
Lamotrigine	Tablet 5 mg	50	112	5	
	Tablet 25 mg	50	112	5	
	Tablet 50 mg	50	112	5	
	Tablet 100 mg	50	112	5	
	Tablet 200 mg	50	112	5	
Lansoprazole	Capsule 15 mg	50	60	5	
	Capsule 30 mg	50	56	5	
		50	112	5	
	Tablet 15 mg (orally disintegrating)	50	56	5	
	Tablet 30 mg (orally disintegrating)	50	56	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
		50	112	5	
Lanthanum	Tablet, chewable, 500 mg (as carbonate hydrate)	50	180	5	
	Tablet, chewable, 750 mg (as carbonate hydrate)	50	180	5	
	Tablet, chewable, 1000 mg (as carbonate hydrate)	50	180	5	
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	50	2	5	
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	50	2	5	
Leflunomide	Tablet 10 mg	50	60	5	
	Tablet 20 mg	50	60	5	
Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	50	56	5	
	Tablet containing lercanidipine hydrochloride 20 mg	50	56	5	
Lercanidipine with enalapril	Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg	50	56	5	
	Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg	50	56	5	
Letrozole	Tablet 2.5 mg	50	60	5	
Levetiracetam	Oral solution 100 mg per mL, 300 mL	50	2	5	
	Tablet 250 mg	50	120	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Levodopa with benserazide	Tablet 500 mg	50	120	5	
	Tablet 1 g	50	120	5	
	Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	50	200	5	
	Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release)	50	200	5	
	Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride)	50	200	5	
	Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride)	50	200	5	
	Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride)	50	200	5	
	Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	50	200	5	
	Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	50	200	5	
Levodopa with carbidopa	Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride)	50	200	5	
	Tablet (modified release) 200 mg-50 mg (as monohydrate)	50	200	5	
	Tablet 100 mg-25 mg (as monohydrate)	50	200	5	
	Tablet 250 mg-25 mg (as monohydrate)	50	200	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Levodopa with carbidopa and entacapone	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	50	400	4	
	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	50	400	4	
	Tablet 100 mg-25 mg (as monohydrate)-200 mg	50	400	4	
	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	50	400	4	
	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	50	400	4	
	Tablet 200 mg-50 mg (as monohydrate)-200 mg	50	400	4	
Linagliptin	Tablet 5 mg	50	60	5	
Linagliptin with metformin	Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride	50	120	5	
	Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride	50	120	5	
	Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride	50	120	5	
Liothyronine	Tablet containing liothyronine sodium 20 micrograms	50	200	2	
Lisinopril	Tablet 5 mg	50	60	5	
	Tablet 10 mg	50	60	5	
	Tablet 20 mg	50	60	5	
Macrogol 3350	Powder for oral solution 510 g	50	2	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Medroxyprogesterone	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	50	2	5	
	Tablet containing medroxyprogesterone acetate 5 mg	50	112	2	
	Tablet containing medroxyprogesterone acetate 10 mg	50	60	2	
		50	200	2	
	Tablet containing medroxyprogesterone acetate 100 mg	50	200	2	
	Tablet containing medroxyprogesterone acetate 200 mg	50	120	2	
	Tablet containing medroxyprogesterone acetate 250 mg	50	120	2	
Mesalazine	Enemas 1 g in 100 mL, 7	50	8	5	
	Enemas 2 g in 60 mL, 7	50	8	5	
	Enemas 4 g in 60 mL, 7	50	8	5	
	Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	50	8	5	
	Sachet containing granules, 500 mg per sachet	50	400	5	
	Sachet containing granules, 1 g per sachet	50	200	5	
	Sachet containing granules, 1.5 g per sachet	50	120	5	
	Sachet containing granules, 3 g per sachet	50	60	5	
	Sachet containing prolonged release granules, 1 g per sachet	50	200	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Sachet containing prolonged release granules, 2 g per sachet	50	120	5	
	Sachet containing prolonged release granules, 4 g per sachet	50	60	5	
	Suppository (moulded) 1 g	50	60	5	
	Suppository 1 g	50	56	5	
	Tablet 250 mg (enteric coated)	50	200	5	
	Tablet 500 mg (enteric coated)	50	400	5	
	Tablet 500 mg (prolonged release)	50	400	5	
	Tablet 800 mg (enteric coated)	50	180	5	
	Tablet 1 g (enteric coated)	50	240	5	
	Tablet 1 g (prolonged release)	50	240	5	
	Tablet 1.2 g (prolonged release)	50	240	5	
	Tablet 1.6 g (enteric coated)	50	240	4	
Metformin	Tablet containing metformin hydrochloride 500 mg	50	200	5	
	Tablet containing metformin hydrochloride 850 mg	50	120	5	
	Tablet containing metformin hydrochloride 1 g	50	180	5	
	Tablet (extended release) containing metformin hydrochloride 500 mg	50	240	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet (extended release) containing metformin hydrochloride 1 g	50	120	5	
Methenamine	Tablet containing methenamine hippurate 1 g	50	200	5	
Methotrexate	Injection 50 mg in 2 mL vial	50	10	5	
Metoprolol	Tablet containing metoprolol tartrate 50 mg	50	200	5	
	Tablet containing metoprolol tartrate 100 mg	50	120	5	
Metoprolol succinate	Tablet 47.5 mg (controlled release)	50	60	5	
	Tablet 95 mg (controlled release)	50	60	5	
	Tablet 190 mg (controlled release)	50	60	5	
Mianserin	Tablet containing mianserin hydrochloride 10 mg	50	100	2	
	Tablet containing mianserin hydrochloride 20 mg	50	100	2	
Minocycline	Tablet 50 mg (as hydrochloride)	50	120	2	
Minoxidil	Tablet 10 mg	50	200	5	
Mirtazapine	Tablet 15 mg	50	60	2	
	Tablet 15 mg (orally disintegrating)	50	60	2	
	Tablet 30 mg	50	60	2	
	Tablet 30 mg (orally disintegrating)	50	60	2	
	Tablet 45 mg	50	60	2	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 45 mg (orally disintegrating)	50	60	2	
Moclobemide	Tablet 150 mg	50	120	2	
	Tablet 300 mg	50	120	2	
Montelukast	Tablet, chewable, 4 mg (as sodium)	50	56	5	
	Tablet, chewable, 5 mg (as sodium)	50	56	5	
Moxonidine	Tablet 200 micrograms	50	60	5	
	Tablet 400 micrograms	50	60	5	
Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	50	600	5	
	Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL	50	2	5	
	Tablet containing mycophenolate mofetil 500 mg	50	300	5	
	Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid	50	240	5	
	Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid	50	240	5	
Nebivolol	Tablet 1.25 mg (as hydrochloride)	50	112	5	
	Tablet 5 mg (as hydrochloride)	50	56	5	
	Tablet 10 mg (as hydrochloride)	50	56	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Nicorandil	Tablets 10 mg, 60	50	2	5	
	Tablets 20 mg, 60	50	2	5	
Nifedipine	Tablet 30 mg (controlled release)	50	60	5	
	Tablet 60 mg (controlled release)	50	60	5	
Nizatidine	Capsule 150 mg	50	120	5	
	Capsule 300 mg	50	60	5	
Norethisterone	Tablet 5 mg	50	60	2	
Olmesartan	Tablet containing olmesartan medoxomil 20 mg	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg	50	60	5	
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	50	60	5	
Olmesartan with amlodipine and hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg	50	60	5	
	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	50	60	5	
	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	50	60	5	
Omeprazole	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	50	60	5	
	Capsule 20 mg	50	60	5	
		50	120	5	
	Tablet 10 mg (as magnesium)	50	60	5	
	Tablet 20 mg	50	60	5	
		50	120	5	
Oxcarbazepine	Tablet 20 mg (as magnesium)	50	60	5	
		50	120	5	
	Oral suspension 60 mg per mL, 250 mL	50	4	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 150 mg	50	200	5	
	Tablet 300 mg	50	200	5	
	Tablet 600 mg	50	200	5	
Oxybutynin	Tablet containing oxybutynin hydrochloride 5 mg	50	200	5	
	Transdermal patches 36 mg, 8	50	2	5	
Pancreatic extract	Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity	50	1000	10	
	Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity	50	400	10	
	Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity	50	400	10	
	Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g	50	6	10	
Pantoprazole	Sachet containing granules 40 mg (as sodium sesquihydrate)	50	60	5	
		50	120	5	
	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	50	60	5	
	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	50	60	5	
		50	120	5	
Paraffin	Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-	50	2	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free)				
	Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	50	4	5	
	Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	50	2	5	
Paroxetine	Tablet 20 mg (as hydrochloride)	50	60	2	
Penicillamine	Tablet 125 mg	50	200	1	
	Tablet 250 mg	50	200	1	
Perampanel	Tablet 4 mg (as hemisesquihydrate)	50	56	5	
	Tablet 6 mg (as hemisesquihydrate)	50	56	5	
	Tablet 8 mg (as hemisesquihydrate)	50	56	5	
	Tablet 10 mg (as hemisesquihydrate)	50	56	5	
	Tablet 12 mg (as hemisesquihydrate)	50	56	5	
Perfluorohexyloctane	Eye drops, 3 mL	50	2	5	
Perindopril	Tablet containing perindopril arginine 2.5 mg	50	60	5	
	Tablet containing perindopril arginine 5 mg	50	60	5	
	Tablet containing perindopril arginine 10 mg	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Perindopril with amlodipine	Tablet containing perindopril erbumine 2 mg	50	60	5	
	Tablet containing perindopril erbumine 4 mg	50	60	5	
	Tablet containing perindopril erbumine 8 mg	50	60	5	
	Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate)	50	60	5	
	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)	50	60	5	
	Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate)	50	60	5	
Perindopril with indapamide	Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate)	50	60	5	
	Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg	50	60	5	
	Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg	50	60	5	
Phenoxyethylpenicillin	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	50	60	5	
	Capsule 250 mg phenoxyethylpenicillin (as potassium)	50	100	5	
Phenytoin	Tablet 250 mg phenoxyethylpenicillin (as potassium)	50	100	5	
	Capsule containing phenytoin sodium 30 mg	50	400	2	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Capsule containing phenytoin sodium 100 mg	50	400	2	
	Oral suspension 30 mg per 5 mL, 500 mL	50	2	3	
	Tablet 50 mg	50	400	2	
Pilocarpine	Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL	50	2	5	
	Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL	50	2	5	
	Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL	50	2	5	
Pioglitazone	Tablet 15 mg (as hydrochloride)	50	56	5	
	Tablet 30 mg (as hydrochloride)	50	56	5	
	Tablet 45 mg (as hydrochloride)	50	56	5	
Pizotifen	Tablet 500 micrograms (as malate)	50	200	2	
Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, 15 mL	50	2	5	
	Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 30	50	4	5	
Potassium chloride	Tablet 600 mg (sustained release)	50	400	1	
Potassium chloride with potassium bicarbonate	Tablet, effervescent, 14 mmol potassium and 8 mmol chloride	50	120	1	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Pramipexole	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg	50	60	5	
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms	50	60	5	
	Tablet containing pramipexole dihydrochloride monohydrate 1 mg	50	200	5	
	Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms	50	200	5	
Pravastatin	Tablet containing pravastatin sodium 10 mg	50	60	5	
	Tablet containing pravastatin sodium 20 mg	50	60	5	
	Tablet containing pravastatin sodium 40 mg	50	60	5	
	Tablet containing pravastatin sodium 80 mg	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Prazosin	Capsule 1 mg (as hydrochloride) (S19A)	50	200	5	
	Tablet 1 mg (as hydrochloride)	50	200	5	
	Tablet 2 mg (as hydrochloride)	50	200	5	
	Tablet 5 mg (as hydrochloride)	50	200	5	
Prednisolone	Oral solution 5 mg (as sodium phosphate) per mL, 30 mL	50	2	5	
	Tablet 1 mg	50	200	4	
	Tablet 5 mg	50	120	4	
Prednisone	Tablet 1 mg	50	200	4	
	Tablet 5 mg	50	120	4	
Probenecid	Tablet 500 mg	50	200	5	
Progesterone	Capsule 100 mg	50	60	5	
Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	50	2	5	
Proprantheline	Tablet containing proprantheline bromide 15 mg	50	400	5	
Propranolol	Tablet containing propranolol hydrochloride 10 mg	50	200	5	
	Tablet containing propranolol hydrochloride 40 mg	50	200	5	
Propylthiouracil	Tablet 50 mg	50	400	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Pyridostigmine	Tablet containing pyridostigmine bromide 10 mg	50	200	5	
	Tablet containing pyridostigmine bromide 180 mg (modified release)	50	200	5	
	Tablet containing pyridostigmine bromide 60 mg	50	300	5	
Quinagolide	Tablet 75 micrograms (as hydrochloride)	50	60	5	
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	50	56	5	
	Tablet containing rabeprazole sodium 20 mg (enteric coated)	50	60	5	
		50	120	5	
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	50	56	5	
Ramipril	Capsule 1.25 mg	50	60	5	
	Capsule 2.5 mg	50	60	5	
	Capsule 5 mg	50	60	5	
	Capsule 10 mg	50	60	5	
	Tablet 1.25 mg	50	60	5	
	Tablet 2.5 mg	50	60	5	
	Tablet 5 mg	50	60	5	
	Tablet 10 mg	50	60	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	50	60	5	
	Tablet 5 mg-5 mg (modified release)	50	60	5	
Rasagiline	Tablet 1 mg (as mesilate)	50	60	5	
Reboxetine	Tablet 4 mg (as mesilate)	50	120	2	
Riluzole	Oral suspension 50 mg per 10 mL, 300 mL	50	4	5	
	Tablet 50 mg	50	112	5	
Risedronic acid	Tablet containing risedronate sodium 5 mg	50	56	5	
	Tablet containing risedronate sodium 35 mg	50	8	5	
	Tablet containing risedronate sodium 150 mg	50	2	5	
	Tablet (enteric coated) containing risedronate sodium 35 mg	50	8	5	
Rivaroxaban	Tablet 2.5 mg	50	120	5	
	Tablet 10 mg	50	60	5	
	Tablet 15 mg	50	56	5	
	Tablet 20 mg	50	56	5	
Rosuvastatin	Tablet 5 mg (as calcium)	50	60	5	
	Tablet 10 mg (as calcium)	50	60	5	
	Tablet 20 mg (as calcium)	50	60	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Rotigotine	Tablet 40 mg (as calcium)	50	60	5	
	Transdermal patch 4.5 mg	50	56	5	
	Transdermal patch 9 mg	50	56	5	
	Transdermal patch 13.5 mg	50	56	5	
	Transdermal patch 18 mg	50	56	5	
Sacubitril with valsartan	Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg	50	112	5	
	Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg	50	112	5	
	Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg	50	112	5	
Safinamide	Tablet 50 mg	50	60	5	
	Tablet 100 mg	50	60	5	
Salmeterol	Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses	50	2	5	
Saxagliptin	Tablet 2.5 mg (as hydrochloride)	50	56	5	
	Tablet 5 mg (as hydrochloride)	50	56	5	
Saxagliptin with dapagliflozin	Tablet containing saxagliptin 5 mg with dapagliflozin 10 mg	50	56	5	
Saxagliptin with metformin	Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride	50	112	5	
	Tablet (modified release) containing 5 mg saxagliptin (as	50	56	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	hydrochloride) with 500 mg metformin hydrochloride				
	Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride	50	56	5	
Selegiline	Tablet containing selegiline hydrochloride 5 mg	50	200	5	
Sertraline	Tablet 50 mg (as hydrochloride)	50	60	2	
	Tablet 100 mg (as hydrochloride)	50	60	2	
Sevelamer	Tablet containing sevelamer carbonate 800 mg	50	360	5	
	Tablet containing sevelamer hydrochloride 800 mg	50	360	5	
Simvastatin	Tablet 5 mg	50	60	5	
	Tablet 10 mg	50	60	5	
	Tablet 20 mg	50	60	5	
	Tablet 40 mg	50	60	5	
	Tablet 80 mg	50	60	5	
Sirolimus	Oral solution 1 mg per mL, 60 mL	50	2	3	
	Tablet 0.5 mg	50	200	3	
	Tablet 1 mg	50	200	3	
	Tablet 2 mg	50	200	3	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Sitagliptin	Tablet 25 mg	50	56	5	
	Tablet 50 mg	50	56	5	
	Tablet 100 mg	50	56	5	
Sitagliptin with metformin	Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride	50	112	5	
	Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride	50	112	5	
	Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride	50	112	5	
	Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride	50	112	5	
	Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride	50	56	5	
Sodium acid phosphate	Tablet, compound effervescent, equivalent to 500 mg phosphorus	50	200	5	
Sodium bicarbonate	Capsule 840 mg	50	200	2	
Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate	Enemas 3.125 g-450 mg-45 mg in 5 mL, 12	50	4	2	
Soy lecithin	Eye spray 10 mg per mL, 10 mL	50	4	5	
Spironolactone	Tablet 25 mg	50	200	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 100 mg	50	200	5	
Sucroferric oxyhydroxide	Tablet, chewable, 2.5 g (equivalent to 500 mg iron)	50	180	5	
Sulfasalazine	Tablet 500 mg	50	400	5	
	Tablet 500 mg (enteric coated)	50	400	5	
Sulthiame	Tablet 50 mg	50	400	2	
	Tablet 200 mg	50	400	2	
Tacrolimus	Capsule 0.5 mg	50	200	3	
	Capsule 0.5 mg (once daily prolonged release)	50	60	3	
	Capsule 0.75 mg	50	200	3	
	Capsule 1 mg	50	200	3	
	Capsule 1 mg (once daily prolonged release)	50	120	3	
	Capsule 2 mg	50	200	3	
	Capsule 3 mg (once daily prolonged release)	50	100	2	
	Capsule 5 mg	50	100	3	
	Capsule 5 mg (once daily prolonged release)	50	60	3	
Tamoxifen	Tablet 20 mg (as citrate)	50	60	5	
		50	120	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Telmisartan	Tablet 40 mg	50	56	5	
	Tablet 80 mg	50	56	5	
Telmisartan with amlodipine	Tablet 40 mg-5 mg (as besilate)	50	56	5	
	Tablet 40 mg-10 mg (as besilate)	50	56	5	
	Tablet 80 mg-5 mg (as besilate)	50	56	5	
	Tablet 80 mg-10 mg (as besilate)	50	56	5	
Telmisartan with hydrochlorothiazide	Tablet 40 mg-12.5 mg	50	56	5	
	Tablet 80 mg-12.5 mg	50	56	5	
	Tablet 80 mg-25 mg	50	56	5	
Teriparatide	Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen	50	2	2	
Testosterone	Transdermal cream 50 mg per mL, 50 mL	50	2	1	
	Transdermal gel 50 mg in 5 g sachet, 30	50	2	5	
	Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2	50	2	4	
	Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses	50	2	5	
Tetrabenazine	Tablet 25 mg	50	224	5	
Thiamine	Tablet containing thiamine hydrochloride 100 mg	50	200	2	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Tiagabine	Tablet 5 mg (as hydrochloride)	50	200	5	
	Tablet 10 mg (as hydrochloride)	50	200	5	
	Tablet 15 mg (as hydrochloride)	50	200	5	
Ticagrelor	Tablet 90 mg	50	112	5	
Tiotropium	Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device)	50	60	5	
	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler)	50	60	5	
	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler)	50	60	5	
	Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)	50	2	5	
	Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations), pack of 2	50	1	5	
Tiotropium with olodaterol	Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses	50	2	5	
	Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2	50	1	5	
Tobramycin	Capsule containing powder for oral inhalation 28 mg (for use in	50	448	2	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	podhaler)				
Topiramate	Solution for inhalation 300 mg in 5 mL	50	112	2	
	Capsule 15 mg	50	120	5	
	Capsule 25 mg	50	120	5	
	Capsule 50 mg	50	120	5	
	Tablet 25 mg	50	120	5	
	Tablet 50 mg	50	120	5	
	Tablet 100 mg	50	120	5	
Toremifene	Tablet 200 mg	50	120	5	
	Tablet 60 mg (as citrate)	50	60	5	
Trandolapril	Capsule 500 micrograms	50	56	5	
	Capsule 1 mg	50	56	5	
	Capsule 2 mg	50	56	5	
	Capsule 4 mg	50	56	5	
Trandolapril with verapamil	Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release)	50	56	5	
	Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release)	50	56	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Tranlycypromine	Tablet 10 mg (as sulfate)	50	100	1	
Travoprost	Eye drops 40 micrograms per mL, 2.5 mL	50	2	5	
Travoprost with timolol	Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	50	2	5	
Umeclidinium	Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses	50	2	5	
Umeclidinium with vilanterol	Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenate) per dose, 30 doses	50	2	5	
Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	50	4	2	
	Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	50	4	2	
	Tablet, crushable, containing sodium valproate 100 mg	50	400	2	
	Tablet (enteric coated) containing sodium valproate 200 mg	50	400	2	
	Tablet (enteric coated) containing sodium valproate 500 mg	50	400	2	
Valsartan	Tablet 80 mg	50	56	5	
	Tablet 160 mg	50	56	5	
	Tablet 320 mg	50	56	5	
Valsartan with hydrochlorothiazide	Tablet 80 mg-12.5 mg	50	56	5	

Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units
Schedule 2

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
	Tablet 160 mg-12.5 mg	50	56	5	
	Tablet 160 mg-25 mg	50	56	5	
	Tablet 320 mg-12.5 mg	50	56	5	
	Tablet 320 mg-25 mg	50	56	5	
Venlafaxine	Capsule (modified release) 75 mg (as hydrochloride)	50	56	2	
	Capsule (modified release) 150 mg (as hydrochloride)	50	56	2	
Verapamil	Tablet containing verapamil hydrochloride 80 mg	50	200	5	
	Tablet containing verapamil hydrochloride 180 mg (sustained release)	50	60	5	
	Tablet containing verapamil hydrochloride 240 mg (sustained release)	50	60	5	
Vigabatrin	Oral powder, sachet 500 mg	50	120	5	
	Tablet 500 mg	50	200	5	
Vildagliptin	Tablet 50 mg	50	120	5	
Vildagliptin with metformin	Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride	50	120	5	
	Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride	50	120	5	
	Tablet containing 50 mg vildagliptin with 1000 mg metformin	50	120	5	

Schedule 2 Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply— increased maximum quantity or number of units

Listed drug	Form	Period (days)	Circumstances:		
			Maximum quantity or number of units	Maximum number of repeats	Other circumstances (if any)
Zonisamide	hydrochloride				
	Capsule 25 mg	50	112	5	
	Capsule 50 mg	50	112	5	
	Capsule 100 mg	50	224	5	

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnotes

Endnote 2—Abbreviation key

Endnote 2—Abbreviation key

ad = added or inserted	o = order(s)
am = amended	Ord = Ordinance
amdt = amendment	orig = original
c = clause(s)	par = paragraph(s)/subparagraph(s) /sub-subparagraph(s)
C[x] = Compilation No. x	pres = present
Ch = Chapter(s)	prev = previous
def = definition(s)	(prev...) = previously
Dict = Dictionary	Pt = Part(s)
disallowed = disallowed by Parliament	r = regulation(s)/rule(s)
Div = Division(s)	reloc = relocated
ed = editorial change	renum = renumbered
exp = expires/expired or ceases/ceased to have effect	rep = repealed
F = Federal Register of Legislation	rs = repealed and substituted
gaz = gazette	s = section(s)/subsection(s)
LA = <i>Legislation Act 2003</i>	Sch = Schedule(s)
LIA = <i>Legislative Instruments Act 2003</i>	Sdiv = Subdivision(s)
(md) = misdescribed amendment can be given effect	SLI = Select Legislative Instrument
(md not incorp) = misdescribed amendment cannot be given effect	SR = Statutory Rules
mod = modified/modification	Sub-Ch = Sub-Chapter(s)
No. = Number(s)	SubPt = Subpart(s)
	<u>underlining</u> = whole or part not commenced or to be commenced

Endnote 3—Legislation history

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
PB 120 of 2015	24 Dec 2015 (F2015L02129)	1 Jan 2016 (s 2)	
PB 4 of 2016	1 Feb 2016 (F2016L00074)	1 Feb 2016 (s 2)	—
PB 12 of 2016	1 Mar 2016 (F2016L00200)	1 Mar 2016 (s 2)	—
PB 21 of 2016	1 Apr 2016 (F2016L00482)	1 Apr 2016 (s 2)	—
PB 32 of 2016	29 Apr 2016 (F2016L00601)	1 May 2016 (s 2)	—
PB 54 of 2016	22 June 2016 (F2016L01055)	1 July 2016 (s 2)	—
PB 66 of 2016	19 July 2016 (F2016L01197)	1 Aug 2016 (s 2)	—
PB 75 of 2016	18 Aug 2016 (F2016L01297)	1 Sept 2016 (s 2)	—
PB 83 of 2016	30 Sept 2016 (F2016L01561)	1 Oct 2016 (s 2)	—
PB 92 of 2016	31 Oct 2016 (F2016L01679)	1 Nov 2016 (s 2)	—
PB 99 of 2016	30 Nov 2016 (F2016L01834)	1 Dec 2016 (s 2)	—
PB 111 of 2016	22 Dec 2016 (F2016L02025)	1 Jan 2017 (s 2)	—
PB 4 of 2017	25 Jan 2017 (F2017L00068)	1 Feb 2017 (s 2)	—
PB 19 of 2017	30 Mar 2017 (F2017L00358)	1 Apr 2017 (s 2)	—
PB 29 of 2017	28 Apr 2017 (F2017L00485)	1 May 2017 (s 2)	—
PB 38 of 2017	31 May 2017 (F2017L00628)	1 June 2017 (s 2)	—
PB 46 of 2017	28 June 2017 (F2017L00774)	1 July 2017 (s 2)	—
PB 65 of 2017	30 Aug 2017 (F2017L01105)	1 Sept 2017 (s 2)	—
PB 74 of 2017	27 Sept 2017 (F2017L01278)	1 Oct 2017 (s 2)	—
PB 87 of 2017	24 Oct 2017 (F2017L01387)	1 Nov 2017 (s 2)	—
PB 94 of 2017	29 Nov 2017 (F2017L01541)	1 Dec 2017 (s 2)	—

Endnotes

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
PB 103 of 2017	18 Dec 2017 (F2017L01629)	1 Jan 2018 (s 2)	—
PB 4 of 2018	24 Jan 2018 (F2018L00054)	1 Feb 2018 (s 2)	—
PB 15 of 2018	28 Feb 2018 (F2018L00164)	1 Mar 2018 (s 2)	—
PB 21 of 2018	28 Mar 2018 (F2018L00422)	1 Apr 2018 (s 2)	—
PB 32 of 2018	30 Apr 2018 (F2018L00546)	1 May 2018 (s 2)	—
PB 39 of 2018	31 May 2018 (F2018L00688)	1 June 2018 (s 2)	—
PB 52 of 2018	29 June 2018 (F2018L00942)	1 July 2018 (s 2)	—
PB 65 of 2018	1 Aug 2018 (F2018L01075)	1 Aug 2018 (s 2)	—
PB 76 of 2018	30 Aug 2018 (F2018L01230)	1 Sept 2018 (s 2)	—
PB 93 of 2018	29 Oct 2018 (F2018L01486)	1 Nov 2018 (s 2)	—
PB 100 of 2018	29 Nov 2018 (F2018L01626)	1 Dec 2018 (s 2)	—
PB 2 of 2019	31 Jan 2019 (F2019L00076)	1 Feb 2019 (s 2)	—
PB 12 of 2019	27 Feb 2019 (F2019L00208)	1 Mar 2019 (s 2)	—
PB 19 of 2019	28 Mar 2019 (F2019L00454)	1 Apr 2019 (s 2)	—
PB 30 of 2019	30 Apr 2019 (F2019L00654)	1 May 2019 (s 2)	—
PB 38 of 2019	30 May 2019 (F2019L00698)	1 June 2019 (s 2)	—
PB 47 of 2019	28 June 2019 (F2019L00908)	1 July 2019 (s 2)	—
PB 60 of 2019	29 July 2019 (F2019L01009)	1 Aug 2019 (s 2)	—
PB 68 of 2019	30 Aug 2019 (F2019L01128)	1 Sept 2019 (s 2)	—
PB 77 of 2019	30 Sept 2019 (F2019L01297)	1 Oct 2019 (s 2)	—
PB 86 of 2019	31 Oct 2019 (F2019L01389)	1 Nov 2019 (s 2)	—
PB 94 of 2019	28 Nov 2019 (F2019L01522)	1 Dec 2019 (s 2)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
PB 105 of 2019	23 Dec 2019 (F2019L01694)	1 Jan 2020 (s 2)	—
PB 3 of 2020	30 Jan 2020 (F2020L00065)	1 Feb 2020 (s 2)	—
PB 15 of 2020	28 Feb 2020 (F2020L00178)	1 Mar 2020 (s 2)	—
PB 21 of 2020	31 Mar 2020 (F2020L00367)	1 Apr 2020 (s 2)	—
PB 34 of 2020	30 Apr 2020 (F2020L00524)	30 Apr 2020 (s 2)	—
PB 56 of 2020	30 June 2020 (F2020L00850)	1 July 2020 (s 2)	—
PB 68 of 2020	31 July 2020 (F2020L00967)	1 Aug 2020 (s 2)	—
PB 79 of 2020	27 Aug 2020 (F2020L01073)	1 Sept 2020 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 8) (PB 90 of 2020)	30 Sept 2020 (F2020L01265)	1 Oct 2020 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 9) (PB 103 of 2020)	30 Oct 2020 (F2020L01357)	1 Nov 2020 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 10) (PB 112 of 2020)	27 Nov 2020 (F2020L01492)	1 Dec 2020 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 11) (PB 125 of 2020)	22 Dec 2020 (F2020L01681)	1 Jan 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 1) (PB 2 of 2021)	28 Jan 2021 (F2021L00075)	1 Feb 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 2) (PB 14 of 2021)	28 Feb 2021 (F2021L00165)	1 Mar 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 3) (PB 23 of 2021)	31 Mar 2021 (F2021L00395)	1 Apr 2021 (s 2)	—

Endnotes

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No.4) (PB 39 of 2021)	30 Apr 2021 (F2021L00518)	1 May 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 5) (PB 47 of 2021)	28 May 2021 (F2021L00655)	1 June 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 6) (PB 61 of 2021)	29 June 2021 (F2021L00893)	1 July 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 7) (PB 75 of 2021)	31 July 2021 (F2021L01054)	1 Aug 2021 (s 2)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 8) (PB 88 of 2021)	31 Aug 2021 (F2021L01219)	1 Sept 2021 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 9) (PB 98 of 2021)	30 Sept 2021 (F2021L01358)	1 Oct 2021 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 10) (PB 110 of 2021)	31 Oct 2021 (F2021L01487)	1 Nov 2021 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 11) (PB 119 of 2021)	30 Nov 2021 (F2021L01651)	1 Dec 2021 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 12) (PB 129 of 2021)	24 Dec 2021 (F2021L01895)	1 Jan 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 1) (PB 2 of 2022)	31 Jan 2022 (F2022L00090)	1 Feb 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 2) (PB 12 of 2022)	28 Feb 2022 (F2022L00202)	1 Mar 2022 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 3) (PB 24 of 2022)	31 Mar 2022 (F2022L00455)	1 Apr 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 4) (PB 34 of 2022)	29 Apr 2022 (F2022L00643)	1 May 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 5) (PB 44 of 2022)	27 May 2022 (F2022L00725)	1 June 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 6) (PB 55 of 2022)	29 June 2022 (F2022L00870)	1 July 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 7) (PB 68 of 2022)	29 July 2022 (F2022L01024)	1 Aug 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 8) (PB 79 of 2022)	26 Aug 2022 (F2022L01110)	1 Sept 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 9) (PB 86 of 2022)	30 Sept 2022 (F2022L01304)	1 Oct 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 10) (PB 112 of 2022)	30 Nov 2022 (F2022L01545)	1 Dec 2022 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 11) (PB 121 of 2022)	23 Dec 2022 (F2022L01752)	1 Jan 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 1) (PB 2 of 2023)	31 Jan 2023 (F2023L00062)	1 Feb 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 2) (PB 22 of 2023)	31 Mar 2023 (F2023L00394)	1 Apr 2023 (s 2(1) item 1)	—

Endnotes

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 3) (PB 35 of 2023)	28 Apr 2023 (F2023L00501)	1 May 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 4) (PB 44 of 2023)	31 May 2023 (F2023L00655)	1 June 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 5) (PB 55 of 2023)	30 June 2023 (F2023L00903)	1 July 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 6) (PB 68 of 2023)	31 July 2023 (F2023L01041)	1 Aug 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 7) (PB 80 of 2023)	31 Aug 2023 (F2023L01148)	1 Sept 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 8) (PB 92 of 2023)	29 Sept 2023 (F2023L01332)	1 Oct 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 9) (PB 113 of 2023)	30 Nov 2023 (F2023L01581)	1 Dec 2023 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 10) (PB 129 of 2023)	22 Dec 2023 (F2023L01748)	1 Jan 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 1) (PB 2 of 2024)	31 Jan 2024 (F2024L00120)	1 Feb 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 2) (PB 16 of 2024)	29 Feb 2024 (F2024L00238)	1 Mar 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 3) (PB 27 of 2024)	28 Mar 2024 (F2024L00423)	1 Apr 2024 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 4) (PB 40 of 2024)	30 Apr 2024 (F2024L00499)	1 May 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 5) (PB 53 of 2024)	31 May 2024 (F2024L00604)	1 June 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 6) (PB 69 of 2024)	28 June 2024 (F2024L00826)	1 July 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 7) (PB 77 of 2024)	31 July 2024 (F2024L00947)	1 Aug 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 8) (PB 86 of 2024)	30 Aug 2024 (F2024L01096)	1 Sept 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 9) (PB 96 of 2024)	30 Sept 2024 (F2024L01238)	1 Oct 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 10) (PB 112 of 2024)	31 Oct 2024 (F2024L01390)	1 Nov 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 11) (PB 125 of 2024)	29 Nov 2024 (F2024L01529)	1 Dec 2024 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 12) (PB 139 of 2024)	24 Dec 2024 (F2024L01732)	1 Jan 2025 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 1) (PB 2 of 2025)	31 Jan 2025 (F2025L00063)	1 Feb 2025 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2) (PB 14 of 2025)	28 Feb 2025 (F2025L00216)	1 Mar 2025 (s 2(1) item 1)	—

Endnotes

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 3) (PB 25 of 2025)	31 Mar 2025 (F2025L00455)	1 Apr 2025 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 4) (PB 41 of 2025)	30 Apr 2025 (F2025L00535)	1 May 2025 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 5) (PB 56 of 2025)	30 May 2025 (F2025L00623)	1 June 2025 (s 2(1) item 1)	—
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 6) (PB 75 of 2025)	30 June 2025 (F2025L00776)	1 July 2025 (s 2(1) item 1)	—

Endnote 4—Amendment history

Endnote 4—Amendment history

Provision affected	How affected
s 2.....	rep LIA s 48D
s 3.....	rep LIA s 48C
s 4.....	rs F2023L01041 am F2023L01581
s 5.....	rs F2023L01581
s 6.....	ed C26 rs F2023L01581
s 7.....	rs F2023L01581
s 8.....	ad F2023L01581
Schedule 1	
Schedule 1.....	am PB 4, 12, 21, 32, 54, 66, 75, 83, 92, 99 and 111 of 2016; PB 4 of 2017; PB 19 of 2017; PB 29 of 2017; PB 38 of 2017; PB 46 of 2017; PB 65 of 2017; PB 74 of 2017; PB 87 of 2017; PB 94 of 2017; PB 103 of 2017; PB 4 of 2018; PB 15 of 2018; PB 21 of 2018; PB 32 of 2018; PB 39 of 2018 ed C26 am PB 52 of 2018; PB 65 of 2018; PB 76 of 2018; PB 93 of 2018 ed C30 am PB 100 of 2018; PB 2 of 2019; PB 12 of 2019 rs PB 19 of 2019 am PB 30 of 2019; PB 38 of 2019; PB 47 of 2019; PB 60 of 2019; PB 68 of 2019; PB 77 of 2019; PB 86 of 2019; PB 94 of 2019; PB 105 of 2019; PB 3 of 2020; PB 15 of 2020; PB 21 of 2020; PB 34 of 2020; PB 56 of 2020; PB 68 of 2020; PB 79 of 2020; PB 90 of 2020; PB 103 of 2020; PB 112 of 2020; PB 125 of 2020; PB 2 of 2021; PB 14 of 2021; F2021L00395; F2021L00518; F2021L00655; F2021L00893; F2021L01054 ed C61 am F2021L01219; F2021L01358; F2021L01487; F2021L01651; F2021L01895; F2022L00090; F2022L00202; F2022L00455; F2022L00643; F2022L00725; F2022L00870; F2022L01024; F2022L01110; F2022L01304; F2022L01545; F2022L01752; F2023L00062; F2023L00394; F2023L00501; F2023L00655; F2023L00903; F2023L01041; F2023L01148; F2023L01332 rs F2023L01581 am F2023L01748; F2024L00120; F2024L00238; F2024L00423; F2024L00499; F2024L00604; F2024L00826 (Sch 1 item 9 md not incorp); F2024L00947; F2024L01096; F2024L01238; F2024L01390; F2024L01529; F2024L01732; F2025L00063; F2025L00216; F2025L00455; F2025L00535; F2025L00623; F2025L00776
Schedule 2	
Schedule 2.....	ad F2023L01581 am F2023L01748; F2024L00238; F2024L00499; F2024L00604; F2024L00826; F2024L01096; F2024L01390; F2024L01529; F2024L01732; F2025L00216; F2025L00455; F2025L00535; F2025L00623; F2025L00776

Endnotes

Endnote 4—Amendment history
